NK1 antagonists

ABSTRACT

A compound having the general structure shown in Formula I: 
                         
or pharmaceutically acceptable salts and/or solvates thereof are useful in treating diseases or conditions mediated by NK 1  receptors, for example various physiological disorders, symptoms or diseases, including emesis, depression, anxiety and cough.

This application claims the benefit of U.S. Provisional Application No.60/584,502, filed Jul. 1, 2004.

FIELD OF THE INVENTION

The present invention relates to novel neurokinin-1 (NK₁ or NK-1)receptor antagonists, pharmaceutical compositions comprising suchcompounds, and methods of treatment using such compounds, to treat NK₁receptor mediated diseases and conditions, including, for example,emesis, depression, anxiety and cough.

BACKGROUND OF THE INVENTION

Tachykinins are peptide ligands for neurokinin receptors. Neurokininreceptors, such as NK₁, NK₂ and NK₃, are involved in a variety ofbiological processes. They can be found in a mammal's nervous andcirculatory systems, as well as in peripheral tissues. Consequently, themodulation of these types of receptors has been studied to potentiallytreat or prevent various mammalian disease states. For instance, NK₁receptors have been reported to be involved in microvascular leakage andmucus secretion. Representative types of neurokinin receptor antagonistsand the disorders that can be treated with them include, for example,sleep, pain, migraine, emesis, nociception and inflammation; see, forexample, U.S. Pat. No. 6,329,401, U.S. Pat. No. 5,760,018, U.S. Pat. No.5,620,989, WO 95/19344, WO 94/13639, WO 94/10165, Wu et al.,Tetrahedron, 56, 6279-6290 (2000), Rombouts et al., Tetrahedron, 59,4721-4731 (2003), and Rogiers et al., Tetrahedron, 57, 8971-8981 (2001).

It would be beneficial to provide a NK₁ antagonist that is potent,selective, and possesses beneficial therapeutic and pharmacologicalproperties, and good metabolic stability. It would further be beneficialto provide a NK₁ antagonist that is effective for treating a variety ofphysiological disorders, symptoms and diseases, while minimizing sideeffects. This invention provides such NK₁ antagonists.

SUMMARY OF THE INVENTION

In one embodiment, the present invention is directed to a compound ofFormula I:

or pharmaceutically acceptable salts and/or solvates thereof, wherein:

R¹ and R² are each independently selected from the group consisting ofH, alkyl, haloalkyl, alkyl substituted with one or more hydroxyl groups,—CN, alkynyl, —N(R⁶)₂, —N(R⁶)—S(O₂)-alkyl, —N(R⁶)—C(O)—N(R⁹)₂,-alkylene-CN,-cycloalkylene-CN, -alkylene-O-alkyl, —C(O)-alkyl,—C(═N—OR⁵)-alkyl, —C(O)—N(R⁹)₂, —C(O)—O-alkyl, -alkylene-C(O)-alkyl,-alkylene-C(O)—O-alkyl, -alkylene-C(O)—N(R⁹)₂,

with the proviso that at least one of R¹ and R² is —CN,

W is ═C(R⁸)— or ═N—;

X is —C(O)— or —S(O₂)—;

Y is selected from the group consisting of —CH₂—, —O—, and —N(R⁶)—C(O)—,with the proviso that:

-   -   (a) the nitrogen atom of —N(R⁶)—C(O)— is bonded to X, and    -   (b) if R¹ and/or R² is

and Y is —O—, X is not —S(O₂)—;

Z is —C(R⁷)₂—, —N(R⁶)—, or —O—;

R³ is selected from the group consisting of H, —CH₂OR⁵, and alkyl;

R⁴ is selected from the group consisting of H, alkyl, cycloalkyl,heterocycloalkyl, heteroaryl, aryl, acyl, aroyl, alkylsulfonyl, andarylsulfonyl;

R⁵ is H or alkyl;

R⁶ is selected from the group consisting of H, alkyl, cycloalkyl, andaryl;

each R⁷ is independently H or alkyl; or

each R⁷, together with the ring carbon to which they are shown attached,form a cycloalkylene ring;

R⁸ is selected from the group consisting of H, alkyl, alkyl substitutedwith one or more hydroxyl groups, —N(R⁶)₂, —N(R⁶)—S(O₂)-alkyl,—N(R⁶)—S(O₂)-aryl, —N(R⁶)—C(O)-alkyl, —N(R⁶)—C(O)-aryl,alkylene-O-alkyl, and —CN;

R⁹ is selected from the group consisting of H, alkyl, and aryl, or eachR⁹, together with the nitrogen to which they are shown attached, form aheterocycloalkyl ring;

Ar¹ and Ar² are each independently selected from the group consisting ofunsubstituted aryl and aryl substituted with 0 to 3 substituentsselected from the group consisting of halogen, alkyl, alkoxy, haloalkyl,haloalkoxy, —CN, —OH, and —NO₂;

n is 0, 1, or 2; and

m is 1, 2, or 3.

In another embodiment, the present invention is directed to apharmaceutical composition comprising a therapeutically effective amountof at least one compound of Formula I, or a pharmaceutically acceptablesalt and/or solvate thereof, and at least one pharmaceuticallyacceptable carrier.

In another embodiment, the present invention is directed to a kitcomprising two or more containers in a single package, wherein eachcontainer in the package comprises a pharmaceutical composition. Atleast one container of the package comprises an effective amount of thecompound of Formula I, or a pharmaceutically acceptable salt and/orsolvate thereof in a pharmaceutically acceptable carrier, and at leastone other container of the package comprises another therapeutic agentin a pharmaceutically acceptable carrier. The pharmaceuticalcompositions of the kit may be used in combination.

In another embodiment, the present invention is directed to a method foraffecting an NK₁ receptor in a patient. The method comprisesadministering to the patient an effective amount of at least onecompound of Formula I or a pharmaceutically acceptable salt and/orsolvate thereof.

In another embodiment, the present invention is directed to a method fortreating an NK₁ receptor mediated condition or disease (i.e., a diseaseassociated with an NK₁ receptor, or a disease involving an NK₁ receptorin part of the disease process) in a patient in need of such treatment.The method comprises administering to the patient an effective amount ofat least one compound of Formula I or a pharmaceutically acceptable saltand/or solvate thereof.

Other features and advantages of the invention will be apparent from thefollowing detailed description, and from the claims.

DETAILED DESCRIPTION OF THE INVENTION

In a first embodiment, the present invention is directed to a compoundof Formula I, or a solvate and/or salt thereof, as described herein.

In yet another embodiment, the compounds of Formula I have the followingstructure IA:

In yet another embodiment of the compounds of Formula I, R³ is C₁₋₆alkyl;

R⁴ is H;

Ar¹ is phenyl;

Ar² is a phenyl substituted with 1 to 3 substituents selected from thegroup consisting of halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkyl,C₁₋₆ haloalkoxy, —CN, and —NO₂; and

n is 1.

In yet another embodiment of the compounds of Formula I, R³ is alkyl;

R⁴ is H;

Ar¹ is phenyl;

Ar² is phenyl substituted with 1 to 3 substituents selected from thegroup consisting of halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkyl,C₁₋₆ haloalkoxy, —CN, and —NO₂; and

n is 1.

In yet another embodiment, the compounds of Formula I have the followingstructure IA:

R³ is C₁₋₆ alkyl;

R⁴ is H;

Ar¹ is phenyl;

Ar² is phenyl substituted with 1 to 3 substituents selected from thegroup consisting of halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkyl,C₁₋₆ haloalkoxy, —CN, and —NO₂; and

n is 1.

In yet another embodiment, the compounds of Formula I have the followingstructure IA:

wherein R¹ and R² are each independently selected from the groupconsisting of H, —CH₃, —CH₂CH₂CH₃, —CH₂Cl, —CH₂F, —CHCl₂, —CHF₂, —CF₃,—CH₂OH, —CH₂CH₂OH, —CH₂CH(OH)CH₃, —CH₂C(OH)(CH₃)₂, —CN, —CH₂CN, —NH₂,—NH—S(O₂)—CH₃, —NH—C(O)—NH₂, —CH₂OCH₃, —C(O)—CH₃, —C(O)—CH₂CH₃,—C(═N—OH)—CH₃, —C(═N—OH)—CH₂CH₃, —C(═N—OCH₃)—CH₃, —C(O)—NH₂,—C(O)—NH(CH₃), —C(O)—O—CH₃ or —C(O)—O—CH₂CH₃, —CH₂—C(O)—CH₃,—CH₂—C(O)O—CH₃, —CH₂—C(O)O—CH₂CH₃, —CH₂C(O)—NH(CH₂CH₃), —CH₂C(O)—NH₂,

R³ is —CH₃;

R⁴ is H;

Ar¹ is phenyl;

Ar² is phenyl substituted with 1 to 3 substituents selected from thegroup consisting of halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkyl,C₁₋₆ haloalkoxy, —CN, and —NO₂; and

n is 1.

In yet another embodiment of the compounds of Formula I, Ar¹ isunsubstituted phenyl or phenyl substituted with 1 to 3 substituentsselected from the group consisting of Cl, F, Br, —OH, C₁₋₆ alkyl, C₁₋₆alkoxy, C₁₋₆ haloalkyl, C₁₋₆ haloalkoxy, —CN, and —NO₂.

In yet another embodiment of the compounds of Formula I, Ar¹ isunsubstituted phenyl.

In yet another embodiment of the compounds of Formula I, Ar² isunsubstituted phenyl or phenyl substituted with 1 to 3 substituentsselected from the group consisting of Cl, F, Br, —OH, C₁₋₆ alkyl, C₁₋₆alkoxy, C₁₋₆ haloalkyl, C₁₋₆ haloalkoxy, —CN, and —NO₂.

In yet another embodiment of the compounds of Formula I, Ar² issubstituted phenyl.

In yet another embodiment of the compounds of Formula I, Ar² is3,5-bis(trifluoromethyl)phenyl.

In yet another embodiment of the compounds of Formula I, R¹ is H.

In yet another embodiment of the compounds of Formula I, R¹ is a C₁₋₆alkyl, for example methyl, ethyl, n-propyl, isopropyl, n-butyl,sec-butyl, t-butyl, n-pentyl, or n-hexyl.

In yet another embodiment of the compounds of Formula I, R¹ is a C₁₋₆haloalkyl, for example —CH₂Cl, —CH₂F, —CHCl₂, —CHF₂, —CF₃.

In yet another embodiment of the compounds of Formula I, R¹ is a C₂₋₆alkynyl, for example —C≡C—H, —C≡C—CH₃, —C≡C—CH₂CH₃, etc.

In yet another embodiment of the compounds of Formula I, R¹ is a C₁₋₆alkyl substituted with one or more hydroxy groups, for example —CH₂OH,—CH₂CH₂OH, —CH₂CH(OH)CH₃, or —CH₂C(OH)(CH₃)₂.

In yet another embodiment of the compounds of Formula I, R¹ is —CN or—C₁₋₆ alkylene-CN, for example —CH₂CN.

In yet another embodiment of the compounds of Formula I, R¹ is —NH₂.

In yet another embodiment of the compounds of Formula I, R¹ is—NH—S(O₂)—C₁₋₆ alkyl, for example —NH—S(O₂)—CH₃.

In yet another embodiment of the compounds of Formula I, R¹ is—NH—C(O)—NH₂.

In yet another embodiment of the compounds of Formula I, R¹ is —C₁₋₆alkylene-O—C₁₋₆ alkyl, for example —CH₂OCH₃.

In yet another embodiment of the compounds of Formula I, R¹ is—C(O)—C₁₋₆ alkyl, for example —C(O)—CH₃ or —C(O)—CH₂CH₃.

In yet another embodiment of the compounds of Formula I, R¹ is—C(═N—OH)—C₁₋₆ alkyl or —C(═N—O—C₁₋₆ alkyl)-C₁₋₆ alkyl, for example—C(═N—OH)—CH₃, —C(═N—OH)—CH₂CH₃, or —C(═N—OCH₃)—CH₃.

In yet another embodiment of the compounds of Formula I, R¹ is—C(O)—NH(C₁₋₆ alkyl), —C(O)—N(C₁₋₆ alkyl)₂, —C(O)—NH(C₆₋₁₀ aryl),—C(O)—N(C₆₋₁₀ aryl)₂, —C(O)—N(C₁₋₆ alkyl)(C₆₋₁₀ aryl), or —C(O)—NH₂, forexample —C(O)—NH₂ or —C(O)—NH(CH₃).

In yet another embodiment of the compounds of Formula I, R¹ is—C(O)—O—C₁₋₆ alkyl, for example —C(O)—O—CH₃ or —C(O)—O—CH₂CH₃.

In yet another embodiment of the compounds of Formula I, R¹ is —C₁₋₆alkylene-C(O)—C₁₋₆ alkyl, for example —CH₂—C(O)—CH₃.

In yet another embodiment of the compounds of Formula I, R¹ is —C₁₋₆alkylene-C(O)—O—C₁₋₆ alkyl, for example —CH₂—C(O)O—CH₃ or—CH₂—C(O)O—CH₂CH₃.

In yet another embodiment of the compounds of Formula I, R¹ is —C₁₋₆alkylene-C(O)—NH₂, —C₁₋₆ alkylene-C(O)—NH(C₁₋₆ alkyl), —C₁₋₆alkylene-C(O)—N(C₁₋₆ alkyl)₂, —C₁₋₆ alkylene-C(O)—NH(C₆₋₁₀ aryl), —C₁₋₆alkylene-C(O)—N(C₆₋₁₀ aryl)₂, or —C₁₋₆ alkylene-C(O)—N(C₁₋₆ alkyl)(C₆₋₁₀aryl), for example —CH₂C(O)—NH(CH₂CH₃) or —CH₂C(O)—NH₂.

In yet another embodiment of the compounds of Formula I, R¹ is one of:

In yet another embodiment of the compounds of Formula I, R² is H.

In yet another embodiment of the compounds of Formula I, R² is a C₁₋₆alkyl, for example methyl, ethyl, n-propyl, isopropyl, n-butyl,sec-butyl, t-butyl, n-pentyl, or n-hexyl.

In yet another embodiment of the compounds of Formula I, R² is a C₁₋₆haloalkyl, for example —CH₂Cl, —CH₂F, —CHCl₂, —CHF₂, —CF₃.

In yet another embodiment of the compounds of Formula I, R² is a C₂₋₆alkynyl, for example —C≡C—H, —C≡C—CH₃, —C≡C—CH₂CH₃, etc.

In yet another embodiment of the compounds of Formula I, R² is a C₁₋₆alkyl substituted with one or more hydroxy groups, for example —CH₂OH,—CH₂CH₂OH, —CH₂CH(OH)CH₃, or —CH₂C(OH)(CH₃)₂.

In yet another embodiment of the compounds of Formula I, R² is —CN or—C₁₋₆ alkylene-CN, for example —CH₂CN or —C(CH₃)₂CN.

In yet another embodiment of the compounds of Formula I, R² is —C₃₋₆cycloalkylene-CN, for example

In yet another embodiment of the compounds of Formula I, R² is —NH₂.

In yet another embodiment of the compounds of Formula I, R² isNH—S(O₂)—C₁₋₆ alkyl, —N(C₁₋₆ alkyl)-S(O₂)—C₁₋₆ alkyl or —N(C₆₋₁₀aryl)-S(O₂)—C₁₋₆ alkyl for example —NH—S(O₂)—CH₃.

In yet another embodiment of the compounds of Formula I, R² is—NH—C(O)—NH₂.

In yet another embodiment of the compounds of Formula I, R² is —C₁₋₆alkylene-O—C₁₋₆ alkyl, for example —CH₂OCH₃.

In yet another embodiment of the compounds of Formula I, R² is—C(O)—C₁₋₆ alkyl, for example —C(O)—CH₃ or —C(O)—CH₂CH₃.

In yet another embodiment of the compounds of Formula I, R² is—C(═N—OH)—C₁₋₆ alkyl or —C(═N—O—C₁₋₆ alkyl)-C₁₋₆ alkyl, for example—C(═N—OH)—CH₃, —C(═N—OH)—CH₂CH₃, or —C(═N—OCH₃)—CH₃.

In yet another embodiment of the compounds of Formula I, R² is—C(O)—NH(C₁₋₆ alkyl), —C(O)—N(C₁₋₆ alkyl)₂, —C(O)—NH(C₆₋₁₀ aryl),—C(O)—N(C₆₋₁₀ aryl)₂, —C(O)—N(C₁₋₆ alkyl)(C₆₋₁₀ aryl), or —C(O)—NH₂, forexample —C(O)—NH₂ or —C(O)—NH(CH₃).

In yet another embodiment of the compounds of Formula I, R² is—C(O)—O—C₁₋₆ alkyl, for example —C(O)—O—CH₃ or —C(O)—O—CH₂CH₃.

In yet another embodiment of the compounds of Formula I, R² is —C₁₋₆alkylene-C(O)—C₁₋₆ alkyl, for example —CH₂—C(O)—CH₃.

In yet another embodiment of the compounds of Formula I, R² is —C₁₋₆alkylene-C(O)—O—C₁₋₆ alkyl, for example —CH₂—C(O)O—CH₃ or—CH₂—C(O)O—CH₂CH₃.

In yet another embodiment of the compounds of Formula I, R² is —C₁₋₆alkylene-C(O)—NH₂, —C₁₋₆ alkylene-C(O)—NH(C₁₋₆ alkyl), —C₁₋₆alkylene-C(O)—N(C₁₋₆ alkyl)₂, —C₁₋₆ alkylene-C(O)—NH(C₆₋₁₀ aryl), —C₁₋₆alkylene-C(O)—N(C₆₋₁₀ aryl)₂, or —C₁₋₆ alkylene-C(O—N(C₁₋₆ alkyl)(C₆₋₁₀aryl), for example —CH₂C(O)—NH(CH₂CH₃) or —CH₂C(O)—NH₂.

In yet another embodiment of the compounds of Formula I, R² is one of:

In yet another embodiment of the compounds of Formula I, R³ is a C₁₋₆alkyl, for example methyl, ethyl, n-propyl, isopropyl, n-butyl,sec-butyl, t-butyl, n-pentyl, or n-hexyl.

In yet another embodiment of the compounds of Formula I, R⁴ is H.

In yet another embodiment of the compounds of Formula I, R⁴ is C₁₋₆alkyl, for example methyl, ethyl, n-propyl, isopropyl, n-butyl,sec-butyl, t-butyl, n-pentyl, or n-hexyl.

In yet another embodiment of the compounds of Formula I, R⁴ is C₃₋₆cycloalkyl, for example cyclopropyl, cyclobutyl, cyclopentyl, orcyclohexyl.

In yet another embodiment of the compounds of Formula I, R⁴ is C₃₋₆heterocycloalkyl, for example pyrrolidinyl, tetrahydrofuranyl,tetrahydrothiophenyl, tetrahydropyranyl, azetidinyl, morpholinyl,piperazinyl, or piperidinyl.

In yet another embodiment of the compounds of Formula I, R⁴ is C₅₋₁₂heteroaryl, for example benzimidazolyl, benzofuranyl, benzothiophenyl,furanyl, indolyl, isoquinolyl, pyrazinyl, pyridinyl, pyrimidinyl,pyrrolyl, quinolinyl, quinoxalinyl, quinazolinyl, thiophenyl,isoxazolyl, triazolyl, thiazolyl, or thiadiazolyl.

In yet another embodiment of the compounds of Formula I, R⁴ is C₆₋₁₀aryl, for example phenyl or naphthyl.

In yet another embodiment of the compounds of Formula I, R⁴ is C₁₋₆acyl, for example —C(O)CH₃, —C(O)CH₂CH₃, —C(O)CH₂CH₂CH₃, —C(O)CH(CH₃)₂,—C(O)C(CH₃)₃, or —C(O)CH₂CH(CH₃)₂.

In yet another embodiment of the compounds of Formula I, R⁴ is C₆₋₁₀aroyl, for example benzoyl or naphthoyl.

In yet another embodiment of the compounds of Formula I, R⁴ is C₁₋₆alkylsulfonyl, for example —S(O₂)CH₃ or —S(O₂)CH₂CH₃.

In yet another embodiment of the compounds of Formula I, R⁴ is C₆₋₁₀arylsulfonyl, for example —S(O₂)-phenyl or —S(O₂)-naphthyl.

In yet another embodiment of the compounds of Formula I, R⁵ is H.

In yet another embodiment of the compounds of Formula I, R⁵ is C₁₋₆alkyl, for example methyl, ethyl, n-propyl, isopropyl, n-butyl,sec-butyl, t-butyl, n-pentyl, or n-hexyl.

In yet another embodiment of the compounds of Formula I, R⁶ is H.

In yet another embodiment of the compounds of Formula I, R⁶ is C₁₋₆alkyl, for example methyl, ethyl, n-propyl, isopropyl, n-butyl,sec-butyl, t-butyl, n-pentyl, or n-hexyl.

In yet another embodiment of the compounds of Formula I, R⁶ is C₃₋₆cycloalkyl, for example cyclopropyl, cyclobutyl, cyclopentyl, orcyclohexyl.

In yet another embodiment of the compounds of Formula I, R⁶ is C₆₋₁₀aryl, for example phenyl or naphthyl.

In yet another embodiment of the compounds of Formula I, R⁷ is H.

In yet another embodiment of the compounds of Formula I, R⁷ is C₁₋₆alkyl, for example methyl, ethyl, n-propyl, isopropyl, n-butyl,sec-butyl, t-butyl, n-pentyl, and n-hexyl.

In yet another embodiment of the compounds of Formula I, each R⁷,together with the carbon atom to which they are shown attached, form aC₃₋₆ cycloalkyl ring, for example

In yet another embodiment of the compounds of Formula I, R⁸ is H.

In yet another embodiment of the compounds of Formula I, R⁸ is C₁₋₆alkyl, for example methyl, ethyl, n-propyl, isopropyl, n-butyl,sec-butyl, t-butyl, n-pentyl, and n-hexyl.

In yet another embodiment of the compounds of Formula I, R⁸ is—NH—S(O₂)—C₁₋₆ alkyl, —N(C₁₋₆ alkyl)-S(O₂)—C₁₋₆ alkyl or —N(C₆₋₁₀aryl)-S(O₂)—C₁₋₆ alkyl for example —NH—S(O₂)—CH₃.

In yet another embodiment of the compounds of Formula I, R⁸ is—NH—S(O₂)—C₆₋₁₀ aryl, —N(C₁₋₆ alkyl)-S(O₂)—C₆₋₁₀ aryl or —N(C₆₋₁₀aryl)-S(O₂)—C₆₋₁₀ aryl, for example —NH—S(O₂)-phenyl or—NH—S(O₂)-4-methylphenyl.

In yet another embodiment of the compounds of Formula I, R⁸ is—NH—C(O)—C₁₋₆ alkyl, —N(C₁₋₆ alkyl)-C(O)—C₁₋₆ alkyl or —N(C₆₋₁₀aryl)-C(O)—C₁₋₆ alkyl for example —NH—S(O₂)—CH₃.

In yet another embodiment of the compounds of Formula I, R⁸ is—NH—C(O)—C₆₋₁₀ aryl, —N(C₁₋₆ alkyl)-C(O)—C₆₋₁₀ aryl or —N(C₆₋₁₀aryl)-C(O)—C₆₋₁₀ aryl, for example —NH—C(O)-phenyl or—NH—C(O)-4-methylphenyl.

In yet another embodiment of the compounds of Formula I, R⁸ is —C₁₋₆alkylene-O—C₁₋₆ alkyl, for example —CH₂OCH₃.

In yet another embodiment of the compounds of Formula I, R⁸ is a C₁₋₆alkyl substituted with one or more hydroxy groups, for example —CH₂OH,—CH₂CH₂OH, —CH₂CH(OH)CH₃, or —CH₂C(OH)(CH₃)₂.

In yet another embodiment of the compounds of Formula I, R⁸ is —CN.

In yet another embodiment of the compounds of Formula I, R⁸ is —NH₂,—N(C₁₋₆ alkyl)₂, —NH(C₁₋₆ alkyl), —N(C₆₋₁₀ aryl)₂, —NH(C₆₋₁₀ aryl),—N(C₃₋₆ cycloalkyl)₂, —NH(C₃₋₆ cycloalkyl), —N(C₁₋₆ alkyl)(C₆₋₁₀ aryl),—N(C₁₋₆ cycloalkyl)(C₆₋₁₀ aryl), or —N(C₁₋₆ cycloalkyl)(C₁₋₆ alkyl).

In yet another embodiment of the compounds of Formula I, R⁹ is H.

In yet another embodiment of the compounds of Formula I, R⁹ is C₁₋₆alkyl, for example methyl, ethyl, n-propyl, isopropyl, n-butyl,sec-butyl, t-butyl, n-pentyl, or n-hexyl.

In yet another embodiment of the compounds of Formula I, R⁹ is C₆₋₁₀aryl, for example phenyl or naphthyl.

In yet another embodiment of the compounds of Formula I, each R⁹together with the nitrogen atom to which they are shown attached, form aC₁₋₆ heterocycloalkyl ring. For example —N(R⁹)₂ forms one of

In yet another embodiment of the compounds of Formula I, X is —C(O)—.

In yet another embodiment of the compounds of Formula I, X is —S(O₂)—.

In yet another embodiment of the compounds of Formula I, Y is —CH₂—.

In yet another embodiment of the compounds of Formula I, Y is —O—.

In yet another embodiment of the compounds of Formula I, Y is—N(H)—C(O)—, —N(C₁₋₆ alkyl)-C(O)—, or —N(C₆₋₁₀ aryl)-C(O)—, for example—N(H)—C(O)—, —N(CH₃)—C(O)—, or —N(phenyl)-C(O)—.

In yet another embodiment of the compounds of Formula I, Z is —CH₂—.

In yet another embodiment of the compounds of Formula I, Z is —C(C₁₋₆alkyl)₂ or —CH(C₁₋₆ alkyl), for example —C(CH₃)₂— or —CH(CH₃)—.

In yet another embodiment of the compounds of Formula I, Z is —NH—.

In yet another embodiment of the compounds of Formula I, Z is —N(C₁₋₆alkyl)-, for example —N(CH₃)— or —N(CH₂CH₃)—.

In yet another embodiment of the compounds of Formula I, Z is —N(C₆₋₁₀aryl)-, for example —N(phenyl)- or —N(naphthyl)-.

In yet another embodiment of the compounds of Formula I, Z is —O—.

In yet another embodiment of the compounds of Formula I, n is 0.

In yet another embodiment of the compounds of Formula I, n is 1.

In yet another embodiment of the compounds of Formula I, n is 2.

In still yet another embodiment, the compounds of Formula I have thefollowing structure IB:

wherein each of R¹ and R² are as shown in the following Table I:

Compound R¹ R² 1

—CN 2

—CN 3

4

5

—CH₂CN 6 —CH₃

7 —CN

8 —C(O)—O—CH₃

9

—CN 10 —C(O)—NH₂

11

—CH₂C(OH)(CH₃)₂ 12 —CH₂OH

13

—CH₂OCH₃ 14 —CH₂OCH₃

15

—CH₂—N—S(O₂)—CH₃ 16

—CH₂C(O)—NH(CH₂CH₃) 17

—CH₂—C(O)O—CH₂CH₃ 18

—C(═N—OH)—CH₂CH₃ 19

—C(O)—CH₂CH₃ 20

—CH₂OCH₃ 21

—C(O)—NH(CH₃) 22 —C(O)—NH(CH₃)

23

—CH₂OH 24

—CH₂CH₂OH 25

—CH₂CH₂OH 26

—CH₂OCH₃ 27 —CH₂OCH₃

28

H 29

—CH₂C(O)—NH₂ 30

—CH₂—C(O)—CH₃ 31

—CH₂—C(O)O—CH₃ 32

—CN 33

—CN 34 —CN

35 —CN

36 —NH—S(O₂)—CH₃ —CN 37 —CN —NH—S(O₂)—CH₃ 38

—CH₂CN 39 —CN —NH₂ 40 —NH₂ —CN 41 —NH—C(O)—NH₂ —CN 42

—CN 43

H 44

H 45

H 46 H

47

H 48 H

49

H 50 H

51

—C(O)—NH₂ 52

—C(═N—OCH₃)—CH₃ 53

—C(O)—CH₃ 54

—C(═N—OH)—CH₃ 55

—C(O)OCH₃ 56

—CH₂Cl 57

—CH₃ 58

—C(═N—OCH₃)—CH₂CH₃ 59 —NHC(O)CH₃

60 H

61

H

In an additional embodiment, the present invention is directed to atreating a disease (or disorder or condition) in a patient in need ofsuch treatment, wherein the disease is selected from the groupconsisting of: (1) respiratory diseases (e.g., chronic lung disease,bronchitis, pneumonia, asthma, allergy, cough and bronchospasm), (2)inflammatory diseases (e.g., arthritis and psoriasis), (3) skindisorders (e.g., atopic dermatitis and contact dermatitis), (4)ophthalmological disorders (e.g., retinitis, ocular hypertension andcataracts), (5) central nervous system conditions, such as depressions(e.g., neurotic depression), anxieties (e.g., general anxiety, socialanxiety and panic anxiety disorders), phobias (e.g., social phobia), andbipolar disorder, (6) addictions (e.g., alcohol dependence andpsychoactive substance abuse), (7) epilepsy, (8) nociception, (9)psychosis, (10) schizophrenia, (11) Alzheimer's disease, (12) AIDSrelated dementia, (13) Towne's disease, (14) stress related disorders(e.g., post traumatic stress disorder), (15) obsessive/compulsivedisorders, (16) eating disorders (e.g., bulimia, anorexia nervosa andbinge eating), (17) sleep disorders, (18) mania, (19) premenstrualsyndrome, (20) gastrointestinal disorders (e.g., irritable bowelsyndrome, Crohn's disease, colitis, and emesis), (21) atherosclerosis,(22) fibrosing disorders (e.g., pulmonary fibrosis), (23) obesity, (24)Type II diabetes, (25) pain related disorders (e.g., headaches, such asmigraines, neuropathic pain, post-operative pain, and chronic painsyndromes), (26) bladder and genitourinary disorders (e.g., interstitialcystitis and urinary incontinence), (27) emesis (e.g.,chemotherapy-induced (e.g., induced by cisplatin, doxorubicin, andtaxane), radiation-induced, motion sickness, ethanol-induced, and postoperative nausea and vomiting), and (28) nausea, comprisingadministering to the patient an effective amount of at least one (e.g.,one) compound of Formula I or a pharmaceutically acceptable salt and/orsolvate thereof.

In still an additional embodiment, the present invention is directed toa method of treating a disease (or disorder or condition) in a patientin need of such treatment, wherein the disease is selected from thegroup consisting of: respiratory diseases (e.g., cough), depression,anxiety, phobia, bipolar disorder, alcohol dependence, psychoactivesubstance abuse, nociception, psychosis, schizophrenia, stress relateddisorders, obsessive/compulsive disorder, bulimia, anorexia nervosa,binge eating, sleep disorders, mania, premenstrual syndrome,gastrointestinal disorders, obesity, pain related disorders (e.g.,headaches, such as migraines, neuropathic pain, post-operative pain, andchronic pain syndromes), bladder disorders, genitourinary disorders,emesis and nausea, comprising administering to the patient an effectiveamount of at least one compound of Formula I or a pharmaceuticallyacceptable salt and/or solvate thereof.

In still an additional embodiment, the present invention also isdirected to a method of treating a disease (or disorder or condition)wherein there is microvascular leakage and mucus secretion in a patientin need of such treatment, comprising administering to the patient aneffective amount of at least one compound of Formula I or apharmaceutically acceptable salt and/or solvate thereof.

In still an additional embodiment, the present invention also isdirected to a method of treating asthma, emesis, nausea, depressions,anxieties, cough and pain related disorders in a patient in need of suchtreatment comprising administering to the patient an effective amount ofat least one compound of Formula I or a pharmaceutically acceptable saltand/or solvate thereof.

In still an additional embodiment, the present invention also isdirected to a method of treating emesis, depression, anxiety and coughin a patient in need of such treatment comprising administering to thepatient an effective amount of at least one compound of Formula I or apharmaceutically acceptable salt and/or solvate thereof.

In still an additional embodiment, the present invention also isdirected to a method for antagonizing an effect of a Substance P at aneurokinin-1 receptor site in a patient in need of such treatment,comprising administering to the patient at least one compound of FormulaI or a pharmaceutically acceptable salt and/or solvate thereof.

In still an additional embodiment, the present invention also isdirected to a method for the blockade of NK₁ receptors in a patient inneed of such treatment, comprising administering to the patient at leastone compound of Formula I or a pharmaceutically acceptable salt and/orsolvate thereof.

In still an additional embodiment, the present invention also isdirected to a method for treating depression and/or anxiety in a patientin need of such treatment comprising administering to the patient aneffective amount of one or more compounds of Formula I or apharmaceutically acceptable salt and/or solvate thereof, in combinationwith an effective amount of one or more anti-depressant agents and/orone or more anti-anxiety agents.

In still an additional embodiment, the present invention also isdirected to a method of treating an NK₁ receptor mediated disease (ordisorder or condition) in a patient in need of such treatment comprisingadministering to the patient an effective amount of one or morecompounds of Formula I or a pharmaceutically acceptable salt and/orsolvate thereof, in combination with an effective amount of one or moreselective serotonin reuptake inhibitors (“SSRIs”).

In still an additional embodiment, the present invention also isdirected to a method of treating depression and/or anxiety in a patientin need of such treatment comprising administering to the patient aneffective amount of one or more compounds of Formula I or apharmaceutically acceptable salt and/or solvate thereof, in combinationwith an effective amount of one or more selective serotonin reuptakeinhibitors.

In yet an additional embodiment, the present invention also is directedto a method of treating an NK₁ receptor mediated disease (or disorder orcondition) in a patient in need of such treatment comprisingadministering to the patient an effective amount of at least onecompound of Formula I or a pharmaceutically acceptable salt and/orsolvate thereof, in combination with at least one therapeutic agentselected from the group consisting of: other types of NK₁ receptorantagonists (e.g., NK₁ receptor antagonists other than those accordingto Formula I of the present invention), prostanoids, H₁ receptorantagonists, α-adrenergic receptor agonists, dopamine receptor agonists,melanocortin receptor agonists, endothelin receptor antagonists,endothelin converting enzyme inhibitors, angiotensin II receptorantagonists, angiotensin converting enzyme inhibitors, neutralmetalloendopeptidase inhibitors, ET_(A) antagonists, renin inhibitors,serotonin 5-HT₃ receptor antagonists (e.g., ondansetron), serotonin5-HT_(2c) receptor agonists, nociceptin receptor agonists,glucocorticoids (e.g., dexamethasone), rho kinase inhibitors, potassiumchannel modulators and inhibitors of multi-drug resistance protein 5.

In yet an additional embodiment, the invention also is directed to amethod for treating an NK₁ mediated disease (or disorder or condition)in a patient in need of such treatment comprising administering to thepatient an effective amount of a compound of Formula I or apharmaceutically acceptable salt and/or solvate thereof, in combinationwith at least one therapeutic agent selected from the group consistingof: prostanoids, such as prostaglandin E1; α-adrenergic agonists, suchas phentolamine mesylate; dopamine receptor agonists, such asapomorphine; angiotensin II antagonists, such as losartan, irbesartan,valsartan and candesartan; ET_(A) antagonists, such as bosentan andABT-627; serotonin 5-HT₃ receptor antagonists, such as ondansetron; andglucocorticoids, such as dexamethasone.

In yet an additional embodiment, the invention also is directed to amethod for treating an NK₁ mediated disease (or disorder or condition)in a patient in need of such treatment comprising administering to thepatient an effective amount of at least one compound of Formula I or apharmaceutically acceptable salt and/or solvate thereof, in combinationwith an effective amount of at least one therapeutic agent selected fromthe group consisting of: other types of NK₁ receptor antagonists, SSRIs,dopamine receptor agonists, serotonin 5-HT₃ receptor antagonists,serotonin 5-HT_(2c) receptor agonists, nociceptin receptor agonists,glucocorticoids and inhibitors of multi-drug resistance protein 5.

In yet an additional embodiment, the invention also is directed to amethod for treating emesis, nausea and/or vomiting in a patient in needof such treatment comprising administering to the patient an effectiveamount of at least one compound of Formula I or a pharmaceuticallyacceptable salt and/or solvate thereof, in combination with an effectiveamount of at least one serotonin 5-HT₃ receptor antagonist (e.g.,ondansetron) and/or at least one glucocorticoid (e.g., dexamethasone).

In still yet an additional embodiment, the present invention also isdirected to a kit comprising, in separate containers in a singlepackage, pharmaceutical compositions for use in combination to treat anNK₁ receptor mediated disease (or disorder or condition), wherein onecontainer comprises a pharmaceutical composition comprising an effectiveamount of a compound of Formula I or a pharmaceutically acceptable saltand/or solvate thereof, in a pharmaceutically acceptable carrier, andwherein, a separate container comprises a pharmaceutical compositioncomprising another therapeutic agent in a pharmaceutically acceptablecarrier, the therapeutic agent being selected from the group consistingof: SSRIs, other types of NK₁ receptor antagonists, prostanoids, H₁receptor antagonists, α-adrenergic receptor agonists, dopamine receptoragonists, melanocortin receptor agonists, endothelin receptorantagonists, endothelin converting enzyme inhibitors, angiotensin IIreceptor antagonists, angiotensin converting enzyme inhibitors, neutralmetalloendopeptidase inhibitors, ET_(A) antagonists, renin inhibitors,serotonin 5-HT₃ receptor antagonists, serotonin 5-HT_(2c) receptoragonists, nociceptin receptor agonists, glucocorticoids, rho kinaseinhibitors, potassium channel modulators and inhibitors of multi-drugresistance protein 5.

In still yet an additional embodiment, the present invention also isdirected to a kit comprising, in separate containers in a singlepackage, pharmaceutical compositions for use in combination to treatdepression and/or anxiety, wherein one container comprises apharmaceutical composition comprising an effective amount of a compoundof Formula I or a pharmaceutically acceptable salt and/or solvatethereof, in a pharmaceutically acceptable carrier, and wherein, aseparate container comprises a pharmaceutical composition comprising anantidepressant agent in a pharmaceutically acceptable carrier, and/orwherein a separate container comprises a pharmaceutical compositioncomprising an antianxiety agent in a pharmaceutically acceptablecarrier.

In still yet an additional embodiment, the present invention also isdirected to a kit comprising, in separate containers in a singlepackage, pharmaceutical compositions for use in combination to treat anNK₁ receptor mediated disease, wherein one container comprises apharmaceutical composition comprising an effective amount of a compoundof Formula I or a pharmaceutically acceptable salt and/or solvatethereof, in a pharmaceutically acceptable carrier, and wherein, aseparate container comprises a pharmaceutical composition comprising anSSRI in a pharmaceutically acceptable carrier.

In still yet an additional embodiment, the present invention also isdirected to a kit comprising, in separate containers in a singlepackage, pharmaceutical compositions for use in combination to treatdepression and/or anxiety, wherein one container comprises apharmaceutical composition comprising an effective amount of a compoundof Formula I or a pharmaceutically acceptable salt and/or solvatethereof, in a pharmaceutically acceptable carrier, and wherein, aseparate container comprises a pharmaceutical composition comprising anSSRI in a pharmaceutically acceptable carrier.

In still yet an additional embodiment, the present invention also isdirected to a kit comprising, in separate containers in a singlepackage, pharmaceutical compositions for use in combination to treatemesis and/or nausea, wherein one container comprises a pharmaceuticalcomposition comprising an effective amount of a compound of Formula I ora pharmaceutically acceptable salt and/or solvate thereof, in apharmaceutically acceptable carrier, and wherein, a separate containercomprises a pharmaceutical composition comprising a serotonin 5-HT₃receptor antagonist in a pharmaceutically acceptable carrier, and/orwherein a separate container comprises a pharmaceutical compositioncomprising a glucocorticoid in a pharmaceutically acceptable carrier.

In still yet an additional embodiment, the present invention also isdirected to a kit comprising, in separate containers in a singlepackage, pharmaceutical compositions for use in combination to treatemesis and/or nausea, wherein one container comprises a pharmaceuticalcomposition comprising an effective amount of a compound of Formula I ora pharmaceutically acceptable salt and/or solvate thereof, in apharmaceutically acceptable carrier, and wherein a separate containercomprises ondansetron, and/or wherein a separate container comprisesdexamethasone.

Another aspect of the invention is to provide a kit comprising, inseparate containers in a single package, pharmaceutical compositions foruse in combination to treat an NK₁ receptor mediated disease, whereinone container comprises a pharmaceutical composition comprising aneffective amount of a compound of Formula I in a pharmaceuticallyacceptable carrier, and wherein, a separate container comprises apharmaceutical composition comprising a therapeutic agent in apharmaceutically acceptable carrier, the therapeutic agent beingselected from the group consisting of: other types of NK₁ receptorantagonists, SSRIs, dopamine receptor agonists, serotonin 5-HT₃ receptorantagonists, serotonin 5-HT_(2c) receptor agonists, nociceptin receptoragonists, glucocorticoids and inhibitors of multi-drug resistanceprotein 5.

Except where stated otherwise, the following definitions applythroughout the specification and claims. When any variable occurs morethan one time in any moiety, its definition on each occurrence isindependent of its definition at every other occurrence. Chemical names,common names, and chemical structures may be used interchangeably todescribe the same structure. These definitions apply regardless ofwhether a term is used by itself or in combination with other terms,unless otherwise indicated. Hence, the definition of “alkyl” applies to“alkyl” as well as the “alkyl” portions of “hydroxyalkyl,” “haloalkyl,”“alkoxy,” etc.

Ac means acetyl.

AcOH (or HOAc) means acetic acid.

Boc means t-butoxycarbonyl.

Bu means butyl.

t-Bu or Bu^(t) means tertiary-butyl.

Bn means benzyl.

Cbz means carbobenzoxy (i.e., Ph-CH₂—O—C(O)—).

DCM means dichloromethane.

DIEA means diisopropylethyl amine.

DMF means dimethylformamide.

DMAP means dimethylaminopyridine.

DMPU means N,N H-dimethyl propylene urea.

DMSO means dimethylsulfoxide.

DPPA means diphenylphosphorazide.

Et means ethyl.

EDC means 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride.

FAB means fast atom bombardment.

HOTs means p-toluene sulfonic acid.

HATU meansO-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluroniumhexafluorophosphate.

HPLC means High Performance Liquid Chromatography.

HRMS means high resolution mass spectroscopy.

LCMS means liquid chromatography/mass spectroscopy

LiHMDS means lithium hexamethyldisilazide.

Me means methyl.

MeOH means methanol.

MS means mass spectroscopy.

Ms or mesyl means methane sulfonyl.

Ni (Ra) means Raney Ni.

OD means optical density.

Ph means phenyl

i-PA (or IPA or iPA) means isopropyl.

PPTS means pyridinium p-toluenesulfonic acid.

PTSA means p-toluene sulfonic acid.

PYBOP means (benzotriazol-1-yloxy)tripyrrolidino phosphoniumhexafluorophosphate.

RT or rt means room temperature.

TBAF means tetrabutylammonium fluoride.

TBAI means tetrabutylammonium iodide.

TFA means trifluoroacetic acid.

THF means tetrahydrofuran.

TLC means Thin Layer Chromatography.

TMS means trimethylsilyl.

TMSCI means trimethylsilyl chloride.

“Tosyl” means toluene sulfonyl.

“Patient” includes both human and animals.

“Mammal” means humans and other mammalian animals.

Portions of chemical formulae enclosed in parentheses and/or bracketsdenote pendant groups. For example, —C(O)— refers to a carbonyl group

—N(alkyl)- refers to a divalent amine group with a pendant alkyl group

“Alkyl” means an aliphatic hydrocarbon group, which may be straight orbranched and comprising about 1 to about 20 carbon atoms in the chain.Preferred alkyl groups contain about 1 to about 12 carbon atoms in thechain. More preferred alkyl groups contain about 1 to about 6 carbonatoms in the chain. Branched means that one or more lower alkyl groupssuch as methyl, ethyl or propyl, are attached to a linear alkyl chain.“Lower alkyl” means a group having about 1 to about 6 carbon atoms inthe chain that may be straight or branched. The term “substituted alkyl”means that the alkyl group may be substituted by one or moresubstituents which may be the same or different, each substituent beingindependently selected from the group consisting of halo, alkyl, aryl,cycloalkyl, cyano, hydroxy, alkoxy, alkylthio, amino, —NH(alkyl),—NH(cycloalkyl), —N(alkyl)₂, carboxy and —C(O)O-alkyl. Non-limitingexamples of suitable alkyl groups include methyl, ethyl, n-propyl,isopropyl and t-butyl.

“Alkylene” means a divalent aliphatic hydrocarbon group, which may bestraight or branched and comprising about 1 to about 20 carbon atoms inthe chain. Preferred alkylene groups contain about 1 to about 12 carbonatoms in the chain. More preferred alkyl groups contain about 1 to about6 carbon atoms in the chain. Non-limiting examples of an alkylene groupinclude methylene (i.e., —CH₂—) and ethylidene (—CH₂CH₂— or —CH(CH₃)—).

“Alkenyl” means an aliphatic hydrocarbon group containing at least onecarbon-carbon double bond and which may be straight or branched andcomprising about 2 to about 15 carbon atoms in the chain. Preferredalkenyl groups have about 2 to about 12 carbon atoms in the chain; andmore preferably about 2 to about 6 carbon atoms in the chain. Branchedmeans that one or more lower alkyl groups such as methyl, ethyl orpropyl, are attached to a linear alkenyl chain. “Lower alkenyl” meansabout 2 to about 6 carbon atoms in the chain, which may be straight orbranched. The term “alkenyl” includes substituted alkenyl which meansthat the alkenyl group may be substituted by one or more substituentswhich may be the same or different, each substituent being independentlyselected from the group consisting of halo, alkyl. aryl, cycloalkyl,cyano, alkoxy and —S(alkyl). Non-limiting examples of suitable alkenylgroups include ethenyl (i.e., vinyl), propenyl, n-butenyl,3-methylbut-2-enyl, n-pentenyl, octenyl and decenyl.

“Alkynyl” means an aliphatic hydrocarbon group containing at least onecarbon-carbon triple bond and which may be straight or branched andcomprising about 2 to about 15 carbon atoms in the chain. Preferredalkynyl groups have about 2 to about 12 carbon atoms in the chain; andmore preferably about 2 to about 4 carbon atoms in the chain. Branchedmeans that one or more lower alkyl groups such as methyl, ethyl orpropyl, are attached to a linear alkynyl chain. “Lower alkynyl” meansabout 2 to about 6 carbon atoms in the chain that may be straight orbranched. Non-limiting examples of suitable alkynyl groups includeethynyl, propynyl, 2-butynyl and 3-methylbutynyl. The term “substitutedalkynyl” means that the alkynyl group may be substituted by one or moresubstituents which may be the same or different, each substituent beingindependently selected from the group consisting of alkyl, aryl andcycloalkyl.

“Aryl” means an aromatic monocyclic or multicyclic ring systemcomprising about 6 to about 14 carbon atoms, preferably about 6 to about10 carbon atoms. The aryl group can be optionally substituted with oneor more “ring system substituents” which may be the same or different,and are as defined herein. Non-limiting examples of suitable aryl groupsinclude phenyl and naphthyl.

“Heteroaryl” means an aromatic monocyclic or multicyclic ring systemcomprising about 5 to about 14 ring atoms, preferably about 5 to about10 ring atoms, in which one or more of the ring atoms is an elementother than carbon, for example nitrogen, oxygen or sulfur, alone or incombination. Preferred heteroaryls contain about 5 to about 6 ringatoms. The “heteroaryl” can be optionally substituted by one or more“ring system substituents” which may be the same or different, and areas defined herein. The prefix aza, oxa or thia before the heteroarylroot name means that at least a nitrogen, oxygen or sulfur atomrespectively, is present as a ring atom. A nitrogen atom of a heteroarylcan be optionally oxidized to the corresponding N-oxide. Non-limitingexamples of suitable heteroaryls include pyridyl, pyrazinyl, furanyl,thienyl, pyrimidinyl, pyridone (including N-substituted pyridones),isoxazolyl, isothiazolyl, oxazolyl, thiazolyl, pyrazolyl, furazanyl,pyrrolyl, pyrazolyl, triazolyl, 1,2,4-thiadiazolyl, pyrazinyl,pyridazinyl, quinoxalinyl, phthalazinyl, oxindolyl,imidazo[1,2-a]pyridinyl, imidazo[2,1-b]thiazolyl, benzofurazanyl,indolyl, azaindolyl, benzimidazolyl, benzothienyl, quinolinyl,imidazolyl, thienopyridyl, quinazolinyl, thienopyrimidyl,pyrrolopyridyl, imidazopyridyl, isoquinolinyl, benzoazaindolyl,1,2,4-triazinyl, benzothiazolyl, tetrazolyl and the like. The term“heteroaryl” also refers to partially saturated heteroaryl moieties suchas, for example, tetrahydroisoquinolyl, tetrahydroquinolyl and the like.

“Aralkyl” or “arylalkyl” means an aryl-alkyl-group in which the aryl andalkyl are as previously described. Preferred aralkyls comprise a loweralkyl group. Non-limiting examples of suitable aralkyl groups includebenzyl, 2-phenethyl and naphthalenylmethyl. The bond to the parentmoiety is through the alkyl.

“Alkylaryl” means an alkyl-aryl-group in which the alkyl and aryl are aspreviously described. Preferred alkylaryls comprise a lower alkyl group.A non-limiting example of a suitable alkylaryl group is tolyl. The bondto the parent moiety is through the aryl.

“Cycloalkyl” means a non-aromatic mono- or multicyclic ring systemcomprising about 3 to about 10 carbon atoms, preferably about 5 to about10 carbon atoms. Preferred cycloalkyl rings contain about 5 to about 7ring atoms. The cycloalkyl can be optionally substituted with one ormore “ring system substituents” which may be the same or different, andare as defined above. Non-limiting examples of suitable monocycliccycloalkyls include cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyland the like. Non-limiting examples of suitable multicyclic cycloalkylsinclude 1-decalinyl, norbornyl, adamantyl and the like, as well aspartially saturated species such as, for example, indanyl,tetrahydronaphthyl and the like.

“Cycloalkylene” means a divalent cycloalkyl ring system, comprisingabout 3 to about 10 carbon atoms, preferably about 5 to about 10 carbonatoms. Preferred cycloalkylene rings contain about 5 to about 7 ringatoms. The cycloalkylene can be optionally substituted with one or more“ring system substituents” which may be the same or different, and areas defined above. Non-limiting example of suitable monocycliccycloalkylenes includes cyclopropylene

“Halogen” means fluorine, chlorine, bromine, or iodine. Preferredhalogens are fluorine, chlorine and bromine. “Halogen” or “halo”substituted groups (e.g., haloalkyl groups) refers to groups substitutedwith one or more fluorine, chlorine, bromine, and/or iodine atoms.

“Ring system substituent” means a substituent attached to an aromatic ornon-aromatic ring system, which, for example, replaces an availablehydrogen on the ring system. Ring system substituents may be the same ordifferent, each being independently selected from the group consistingof alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, alkylaryl,heteroaralkyl, heteroarylalkenyl, heteroarylalkynyl, alkylheteroaryl,hydroxy, hydroxyalkyl, alkoxy, aryloxy, aralkoxy, acyl, aroyl, halo,nitro, cyano, carboxy, alkoxycarbonyl, aryloxycarbonyl,aralkoxycarbonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl,alkylthio, arylthio, heteroarylthio, aralkylthio, heteroaralkylthio,cycloalkyl, heterocycloalkyl, —C(═N—CN)—NH₂, —C(═NH)—NH₂,—C(═NH)—NH(alkyl), Y₁Y₂N—, Y₁Y₂N-alkyl-, Y₁Y₂NC(O)—, Y₁Y₂NSO₂— and—SO₂NY₁Y₂, wherein Y₁ and Y₂ can be the same or different and areindependently selected from the group consisting of hydrogen, alkyl,aryl, cycloalkyl, and aralkyl. “Ring system substituent” may also mean asingle moiety which simultaneously replaces two available hydrogens ontwo adjacent carbon atoms (one H on each carbon) on a ring system.Examples of such moiety are methylene dioxy, ethylenedioxy, —C(CH₃)₂—and the like which form moieties such as, for example:

“Heterocycloalkyl” means a non-aromatic saturated monocyclic ormulticyclic ring system comprising about 3 to about 10 ring atoms,preferably about 5 to about 10 ring atoms, in which one or more of theatoms in the ring system is an element other than carbon, for examplenitrogen, oxygen or sulfur, alone or in combination. There are noadjacent oxygen and/or sulfur atoms present in the ring system.Preferred heterocycloalkyls contain about 5 to about 6 ring atoms. Theprefix aza, oxa or thia before the heterocycloalkyl root name means thatat least a nitrogen, oxygen or sulfur atom respectively is present as aring atom. Any —NH in a heterocycloalkyl ring may be present inprotected form such as, for example, an —N(Boc), —N(CBz), —N(Tos) groupand the like; such protected functional groups are also considered partof this invention. The heterocycloalkyl can be optionally substituted byone or more “ring system substituents” which may be the same ordifferent, and are as defined herein. The nitrogen or sulfur atom of theheterocycloalkyl can be optionally oxidized to the correspondingN-oxide, S-oxide or S,S-dioxide. Non-limiting examples of suitablemonocyclic heterocycloalkyl rings include piperidyl, pyrrolidinyl,piperazinyl, morpholinyl, thiomorpholinyl, thiazolidinyl, 1,4-dioxanyl,tetrahydrofuranyl, tetrahydrothiophenyl, lactam, lactone, and the like.

It should be noted that in hetero-atom containing ring systems of thisinvention, there are no hydroxyl groups on carbon atoms adjacent to a N,O or S, as well as there are no N or S groups on carbon adjacent toanother heteroatom. Thus, for example, in the ring:

there is no —OH attached directly to carbons marked 2 and 5.

It should also be noted that tautomeric forms such as, for example, themoieties:

are considered equivalent in certain embodiments of this invention.

“Alkynylalkyl” means an alkynyl-alkyl-group in which the alkynyl andalkyl are as previously described. Preferred alkynylalkyls contain alower alkynyl and a lower alkyl group. The bond to the parent moiety isthrough the alkyl. Non-limiting examples of suitable alkynylalkyl groupsinclude propargylmethyl.

“Heteroaralkyl” means a heteroaryl-alkyl-group in which the heteroaryland alkyl are as previously described. Preferred heteroaralkyls containa lower alkyl group. Non-limiting examples of suitable aralkyl groupsinclude pyridylmethyl, and quinolin-3-ylmethyl. The bond to the parentmoiety is through the alkyl.

“Hydroxyalkyl” means a HO-alkyl-group in which alkyl is as previouslydefined. The “alkyl” portion of the hydroxyalkyl is preferably a loweralkyl. Non-limiting examples of suitable hydroxyalkyl groups includehydroxymethyl and 2-hydroxyethyl.

“Acyl” means an H—C(O)—, alkyl-C(O)— or cycloalkyl-C(O)—, group in whichthe various groups are as previously described. The bond to the parentmoiety is through the carbonyl. Preferred acyls contain a lower alkyl.Non-limiting examples of suitable acyl groups include formyl, acetyl andpropanoyl.

“Aroyl” means an aryl-C(O)— group in which the aryl group is aspreviously described. The bond to the parent moiety is through thecarbonyl. Non-limiting examples of suitable groups include benzoyl and1-naphthoyl.

“Alkoxy” means an alkyl-O— group in which the alkyl group is aspreviously described. Non-limiting examples of suitable alkoxy groupsinclude methoxy, ethoxy, n-propoxy, isopropoxy and n-butoxy. The bond tothe parent moiety is through the ether oxygen.

“Aryloxy” means an aryl-O— group in which the aryl group is aspreviously described. Non-limiting examples of suitable aryloxy groupsinclude phenoxy and naphthoxy. The bond to the parent moiety is throughthe ether oxygen.

“Aralkyloxy” means an aralkyl-O— group in which the aralkyl group is aspreviously described. Non-limiting examples of suitable aralkyloxygroups include benzyloxy and 1- or 2-naphthalenemethoxy. The bond to theparent moiety is through the ether oxygen.

“Alkylthio” means an alkyl-S— group in which the alkyl group is aspreviously described. Non-limiting examples of suitable alkylthio groupsinclude methylthio and ethylthio. The bond to the parent moiety isthrough the sulfur.

“Arylthio” means an aryl-S— group in which the aryl group is aspreviously described. Non-limiting examples of suitable arylthio groupsinclude phenylthio and naphthylthio. The bond to the parent moiety isthrough the sulfur.

“Aralkylthio” means an aralkyl-S— group in which the aralkyl group is aspreviously described. Non-limiting example of a suitable aralkylthiogroup is benzylthio. The bond to the parent moiety is through thesulfur.

“Alkoxycarbonyl” means an alkyl-O—CO— group. Non-limiting examples ofsuitable alkoxycarbonyl groups include methoxycarbonyl andethoxycarbonyl. The bond to the parent moiety is through the carbonyl.

“Aryloxycarbonyl” means an aryl-O—C(O)— group. Non-limiting examples ofsuitable aryloxycarbonyl groups include phenoxycarbonyl andnaphthoxycarbonyl. The bond to the parent moiety is through thecarbonyl.

“Aralkoxycarbonyl” means an aralkyl-O—C(O)— group. Non-limiting exampleof a suitable aralkoxycarbonyl group is benzyloxycarbonyl. The bond tothe parent moiety is through the carbonyl.

“Alkylsulfonyl” means an alkyl-S(O₂)— group. Preferred groups are thosein which the alkyl group is lower alkyl. The bond to the parent moietyis through the sulfonyl.

“Arylsulfonyl” means an aryl-S(O₂)— group. The bond to the parent moietyis through the sulfonyl.

The term “substituted” means that one or more hydrogens on thedesignated atom is replaced with a selection from the indicated group,provided that the designated atom's normal valency under the existingcircumstances is not exceeded, and that the substitution results in astable compound. Combinations of substituents and/or variables arepermissible only if such combinations result in stable compounds. By“stable compound” or “stable structure” is meant a compound that issufficiently robust to survive isolation to a useful degree of purityfrom a reaction mixture, and formulation into an efficacious therapeuticagent.

The term “optionally substituted” means optional substitution with thespecified groups, radicals or moieties.

The term “isolated” or “in isolated form” for a compound refers to thephysical state of said compound after being isolated from a syntheticprocess or natural source or combination thereof. The term “purified” or“in purified form” for a compound refers to the physical state of saidcompound after being obtained from a purification process or processesdescribed herein or well known to the skilled artisan, in sufficientpurity to be characterizable by standard analytical techniques describedherein or well known to the skilled artisan.

It should also be noted that any heteroatom with unsatisfied valences inthe text, schemes, examples and Tables herein is assumed to have one ormore hydrogen atoms to satisfy the valences.

When a ring system (e.g., cycloalkyl, heterocycloalkyl, aryl, orheteroaryl) is substituted with a number of substituents varying withinan expressly defined range, it is understood that the total number ofsubstituents does not exceed the normal available valencies under theexisting conditions. Thus, for example, a phenyl ring substituted with“n” substituents (where “n” ranges from 0 to 5) can have 0 to 5substituents, whereas it is understood that a pyridinyl ring substitutedwith “n” substituents has a number of substituents ranging from 0 to 4.

When a functional group in a compound is termed “protected”, this meansthat the group is in modified form to preclude undesired side reactionsat the protected site when the compound is subjected to a reaction.Suitable protecting groups will be recognized by those with ordinaryskill in the art as well as by reference to standard textbooks such as,for example, T. W. Greene et al, Protective Groups in Organic Synthesis(1991), Wiley, New York, herein incorporated by reference.

When any variable (e.g., aryl, heterocycloalkyl, R², etc.) occurs morethan one time in any constituent or in Formula I, its definition on eachoccurrence is independent of its definition at every other occurrence.

As used herein, the term “composition” is intended to encompass aproduct comprising the specified ingredients in the specified amounts,as well as any product which results, directly or indirectly, fromcombination of the specified ingredients in the specified amounts.

“Alkylheteroaryl” means an alkyl group attached to a parent moiety via aheteroaryl group.

“Alkylsulfinyl” means an alkyl-S(O)— group. Preferred groups are thosein which the alkyl group is lower alkyl. The bond to the parent moietyis through the sulfinyl.

“Aralkenyl” means an aryl-alkenyl-group in which the aryl and alkenylare as previously described. Preferred aralkenyls contain a loweralkenyl group. Non-limiting examples of suitable aralkenyl groupsinclude 2-phenethenyl and 2-naphthylethenyl. The bond to the parentmoiety is through the alkenyl.

“Aralkylthio” means an aralkyl-S— group in which the aralkyl group is aspreviously described. Non-limiting example of a suitable aralkylthiogroup is benzylthio. The bond to the parent moiety is through thesulfur.

“Aryloxycarbonyl” means an aryl-O—C(O)— group. Non-limiting examples ofsuitable aryloxycarbonyl groups include phenoxycarbonyl andnaphthoxycarbonyl. The bond to the parent moiety is through thecarbonyl.

“Arylsulfinyl” means an aryl-S(O)— group. Non-limiting examples ofsuitable arylsulfinyl groups include phenylsulfinyl andnaphthylsulfinyl. The bond to the parent moiety is through the sulfinyl.

A carbamate group means a —O—C(O)—N(alkyl or aryl)-group, and a ureagroup means a —N(alkyl or aryl)-C(O)—N(alkyl or aryl)-group.Representative carbamate and urea groups may include the following:

“Cycloalkenyl” means a non-aromatic mono or multicyclic ring systemcomprising about 3 to about 10 carbon atoms, preferably about 5 to about10 carbon atoms, which contains at least one carbon-carbon double bond.Preferred cycloalkenyl rings contain about 5 to about 7 ring atoms. Thecycloalkenyl can be optionally substituted with one or more “ring systemsubstituents” which may be the same or different, and are as definedabove. Non-limiting examples of suitable monocyclic cycloalkenylsinclude cyclopentenyl, cyclohexenyl, cycloheptenyl, and the like.Non-limiting example of a suitable multicyclic cycloalkenyl isnorbornylenyl.

“Cycloalkylamino” means a cycloalkyl group as defined herein attached tothe parent moiety through a nitrogen atom.

“Cycloalkylaminocarbonyl” means a cyclic alkyl group attached to anitrogen atom, which is attached to a carbonyl group; the whole may bereferred to as a substituted amide.

“Heteroalkyl” means an alkyl as defined herein, in which at least onethe atoms is an element other than carbon, for example nitrogen, oxygenor sulfur, alone or in combination.

“Heteroaralkenyl” means a heteroaryl-alkenyl-group in which theheteroaryl and alkenyl are as previously described. Preferredheteroaralkenyls contain a lower alkenyl group. Non-limiting examples ofsuitable heteroaralkenyl groups include 2-(pyrid-3-yl)ethenyl and2-(quinolin-3-yl)ethenyl. The bond to the parent moiety is through thealkenyl.

“Heteroaralkyl” means a heteroaryl-alkyl-group in which the heteroaryland alkyl are as previously described. Preferred heteroaralkyls containa lower alkyl group. Non-limiting examples of suitable aralkyl groupsinclude pyridylmethyl, 2-(furan-3-yl)ethyl and quinolin-3-ylmethyl. Thebond to the parent moiety is through the alkyl.

“Heteroaralkylthio” means a heteroaryl-alkyl-S group wherein the groupis attached to the parent moiety through the sulfur.

“Heteroarylsulfinyl” means a heteroaryl-S(O)— group wherein theheteroaryl is as defined herein and the heteroarylsulfinyl group isattached to the parent moiety through the sulfinyl.

“Heteroarylsulfonyl” means a heteroaryl-S(O₂)— group wherein theheteroaryl is as defined herein and the heteroarylsulfonyl group isattached to the parent moiety through the sulfonyl.

“Heteroarylthio” means a heteroaryl-S— group wherein the heteroaryl isas defined herein and the heteroarylsulfinyl group is attached to theparent moiety through the sulfur.

“Heterocycloalkenyl” means a non-aromatic monocyclic or multicyclic ringsystem comprising about 3 to about 10 ring atoms, preferably about 5 toabout 10 ring atoms, in which one or more of the atoms in the ringsystem is an element other than carbon, for example nitrogen, oxygen orsulfur atom, alone or in combination, and which contains at least onecarbon-carbon double bond or carbon-nitrogen double bond. There are noadjacent oxygen and/or sulfur atoms present in the ring system.Preferred heterocycloalkenyl rings contain about 5 to about 6 ringatoms. The prefix aza, oxa or thia before the heterocycloalkenyl rootname means that at least a nitrogen, oxygen or sulfur atom respectivelyis present as a ring atom. The heterocycloalkenyl can be optionallysubstituted by one or more ring system substituents, wherein “ringsystem substituent” is as defined above. The nitrogen or sulfur atom ofthe heterocycloalkenyl can be optionally oxidized to the correspondingN-oxide, S-oxide or S,S-dioxide. Non-limiting examples of suitablemonocyclic azaheterocycloalkenyl groups include1,2,3,4-tetrahydropyridine, 1,2-dihydropyridyl, 1,4-dihydropyridyl,1,2,3,6-tetrahydropyridine, 1,4,5,6-tetrahydropyrimidine, 2-pyrrolinyl,3-pyrrolinyl, 2-imidazolinyl, 2-pyrazolinyl, and the like. Non-limitingexamples of suitable oxaheterocycloalkenyl groups include3,4-dihydro-2H-pyran, dihydrofuranyl, fluorodihydrofuranyl, and thelike. Non-limiting example of a suitable multicyclicoxaheterocycloalkenyl group is 7-oxabicyclo[2.2.1]heptenyl. Non-limitingexamples of suitable monocyclic thiaheterocycloalkenyl rings includedihydrothiophenyl, dihydrothiopyranyl, and the like.

“Heterocyclic” means, in addition to the heteroaryl groups definedbelow, saturated and unsaturated cyclic organic groups having at leastone O, S and/or N atom interrupting a carbocyclic ring structure thatconsists of one ring or two fused rings, wherein each ring is 5-, 6- or7-membered and may or may not have double bonds that lack delocalized pielectrons, which ring structure has from 2 to 8, preferably from 3 to 6carbon atoms, e.g., 2- or 3-piperidinyl, 2- or 3-piperazinyl, 2- or3-morpholinyl, or 2- or 3-thiomorpholinyl.

“Sulfonamide” means a sulfonyl group attached to a parent moiety throughan amide.

As is well known in the art, a bond drawn from a particular atom whereinno moiety is depicted at the terminal end of the bond indicates a methylgroup bound through that bond to the atom. For example:

It should also be noted that throughout the specification and Claimsappended hereto, that any formula, compound, moiety or chemicalillustration with unsatisfied valences is assumed to have the hydrogenatom to satisfy the valences unless the context indicates a bond.

With reference to the number of moieties (e.g., substituents, groups orrings) in a compound, unless otherwise defined, the phrases “one ormore” and “at least one” mean that there can be as many moieties aschemically permitted, and the determination of the maximum number ofsuch moieties is well within the knowledge of those skilled in the art.

The wavy line

as a bond generally indicates a mixture of, or either of, the possibleisomers, e.g., containing (R)- and (S)-stereochemistry. For example,

When the stereochemistry in a structure is not expressly indicated, thestructure can have a mixture of, or any of the individual possiblestereoisomers. Thus, when the stereochemistry is not explicitlyindicated in a structure, the structure includes all stereochemicalconfigurations having the indicated connectivity (e.g., all possibleenantiomers or diastereomers), as well as mixtures of such stereoisomers(e.g., racemic mixtures). For example,

Lines drawn into the ring systems, such as, for example:

indicate that the indicated line (bond) may be attached to any of thesubstitutable ring carbon atoms.

Prodrugs and solvates of the compounds of the invention are alsocontemplated herein. The term “prodrug”, as employed herein, denotes acompound that is a drug precursor which, upon administration to asubject, undergoes chemical conversion by metabolic or chemicalprocesses to yield a compound of Formula I or a salt and/or solvatethereof. A discussion of prodrugs is provided in T. Higuchi and V.Stella, Pro-drugs as Novel Delivery Systems (1987) Volume 14 of theA.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design,(1987) Edward B. Roche, ed., American Pharmaceutical Association andPergamon Press, both of which are incorporated herein by referencethereto.

“Solvate” means a physical association of a compound of this inventionwith one or more solvent molecules. This physical association involvesvarying degrees of ionic and covalent bonding, including hydrogenbonding. In certain instances the solvate will be capable of isolation,for example when one or more solvent molecules are incorporated in thecrystal lattice of the crystalline solid. “Solvate” encompasses bothsolution-phase and isolatable solvates. Non-limiting examples ofsuitable solvates include ethanolates, methanolates, and the like. A“hydrate” is a solvate wherein the solvent molecule is H₂O.

“Effective amount” or “therapeutically effective amount” is meant todescribe an amount of compound or a composition of the present inventioneffective in antagonizing the neurokinin-1 receptor and thus producingthe desired therapeutic effect in a suitable patient.

The compounds of Formula I form salts that are also within the scope ofthis invention. Reference to a compound of Formula I herein isunderstood to include reference to salts thereof, unless otherwiseindicated. The term “salt(s)”, as employed herein, denotes acidic saltsformed with inorganic and/or organic acids, as well as basic saltsformed with inorganic and/or organic bases. In addition, when a compoundof Formula I contains both a basic moiety, such as, but not limited to apyridine or imidazole, and an acidic moiety, such as, but not limited toa carboxylic acid, zwitterions (“inner salts”) may be formed and areincluded within the term “salt(s)” as used herein. Pharmaceuticallyacceptable (i.e., non-toxic, physiologically acceptable) salts arepreferred, although other salts are also useful. Salts of the compoundsof the Formula I may be formed, for example, by reacting a compound ofFormula I with an amount of acid or base, such as an equivalent amount,in a medium such as one in which the salt precipitates or in an aqueousmedium followed by lyophilization.

Exemplary acid addition salts include acetates, adipates, alginates,ascorbates, aspartates, benzoates, benzenesulfonates, bisulfates,borates, butyrates, citrates, camphorates, camphorsulfonates,cyclopentanepropionates, digluconates, dodecylsulfates,ethanesulfonates, fumarates, glucoheptanoates, glycerophosphates,hemisulfates, heptanoates, hexanoates, hydrochlorides, hydrobromides,hydroiodides, 2-hydroxyethanesulfonates, lactates, maleates,methanesulfonates, methyl sulfates, 2-naphthalenesulfonates,nicotinates, nitrates, oxalates, pamoates, pectinates, persulfates,3-phenylpropionates, phosphates, picrates, pivalates, propionates,salicylates, succinates, sulfates, sulfonates (such as those mentionedherein), tartarates, thiocyanates, toluenesulfonates (also known astosylates,) undecanoates, and the like.

Exemplary basic salts include ammonium salts, alkali metal salts such assodium, lithium, and potassium salts, alkaline earth metal salts such ascalcium and magnesium salts, aluminum salts, zinc salts, salts withorganic bases (for example, organic amines) such as benzathines,diethylamine, dicyclohexylamines, hydrabamines (formed withN,N-bis(dehydroabietyl)ethylenediamine), N-methyl-D-glucamines,N-methyl-D-glucamides, t-butyl amines, piperazine,phenylcyclohexylamine, choline, tromethamine, and salts with amino acidssuch as arginine, lysine and the like. Basic nitrogen-containing groupsmay be quarternized with agents such as lower alkyl halides (e.g.methyl, ethyl, propyl, and butyl chlorides, bromides and iodides),dialkyl sulfates (e.g. dimethyl, diethyl, dibutyl, and diamyl sulfates),long chain halides (e.g. decyl, lauryl, myristyl and stearyl chlorides,bromides and iodides), aralkyl halides (e.g. benzyl and phenethylbromides), and others. Acids (and bases) which are generally consideredsuitable for the formation of pharmaceutically useful salts from basic(or acidic) pharmaceutical compounds are discussed, for example, by S.Berge et al, Journal of Pharmaceutical Sciences (1977) 66(1) 1-19; P.Gould, International J. of Pharmaceutics (1986) 33 201-217; Anderson etal, The Practice of Medicinal Chemistry (1996), Academic Press, NewYork; in The Orange Book (Food & Drug Administration, Washington, D.C.on their website); and P. Heinrich Stahl, Camille G. Wermuth (Eds.),Handbook of Pharmaceutical Salts: Properties, Selection, and Use, (2002)Int'l. Union of Pure and Applied Chemistry, pp. 330-331, each of whichis incorporated herein by reference.

All such acid salts and base salts are intended to be pharmaceuticallyacceptable salts within the scope of the invention and all acid and basesalts are considered equivalent to the free forms of the correspondingcompounds for purposes of the invention.

Compounds of Formula I and salts, solvates and prodrugs thereof, mayexist in their tautomeric form (for example, as an amide or iminoether). All such tautomeric forms are contemplated herein as part of thepresent invention.

Polymorphic forms of the compounds of Formula I, and of the salts,solvates, and/or prodrugs thereof, are intended to be included in thepresent invention.

All stereoisomers (for example, geometric isomers, optical isomers andthe like) of the present compounds (including those of the salts,solvates and prodrugs of the compounds as well as the salts and solvatesof the prodrugs), such as those which may exist due to asymmetriccarbons on various substituents, including enantiomeric forms (which mayexist even in the absence of asymmetric carbons), rotameric forms,atropisomers, and diastereomeric forms, are contemplated within thescope of this invention. Individual stereoisomers of the compounds ofthe invention may, for example, be substantially free of other isomers,or may be admixed, for example, as racemates or with all other, or otherselected, stereoisomers. The chiral centers of the present invention canhave the S or R configuration as defined by the IUPAC 1974Recommendations. The use of the terms “salt”, “solvate” “prodrug” andthe like, is intended to equally apply to the salt, solvate and prodrugof enantiomers, stereoisomers, rotamers, tautomers, racemates orprodrugs of the inventive compounds. “At least one”, examples include1-3, 1-2 or 1.

Compounds of Formula I are effective antagonists of the NK₁ receptor,and have an effect on its endogenous agonist, Substance P, at the NK₁receptor site, and therefore, can be useful in treating diseases,disorders, or conditions caused or aggravated by the activity of thereceptor.

The in vitro and in vivo NK₁, NK₂ and NK₃ activities of the compounds ofFormula I can be determined by various procedures known in the art, suchas a test for their ability to inhibit the activity of the NK₁ agonistSubstance P. The percent inhibition of neurokinin agonist activity isthe difference between the percent of maximum specific binding (“MSB”)and 100%. The percent of MSB is defined by the following equation,wherein “dpm” represents “disintegrations per minute”:

${\%\mspace{14mu}{MSB}} = {\frac{\left( {{dpm}\mspace{14mu}{of}\mspace{14mu}{unknown}} \right) - \left( {{dpm}\mspace{14mu}{of}\mspace{14mu}{nonspecific}\mspace{14mu}{binding}} \right)}{\left( {{dpm}\mspace{14mu}{of}\mspace{14mu}{total}\mspace{14mu}{binding}} \right) - \left( {{dpm}\mspace{14mu}{of}\mspace{14mu}{nonspecific}\mspace{14mu}{binding}} \right)} \times 100.}$The concentration at which the compound produces 50% inhibition ofbinding is then used to determine an inhibition constant (“K_(i)”) usingthe Chang-Prusoff equation.

In vivo activity may be measured by inhibition of an agonist-inducedfoot tapping in a gerbil, as described in Science, 281, 1640-1695(1998), which is herein incorporated by reference in its entirety. Itwill be recognized that compounds of Formula I can exhibit NK₁antagonist activities of varying degrees. For instance, certaincompounds can exhibit stronger NK₁ antagonist activities than others.

The compounds of the present invention exhibit potent affinities for theNK₁ receptor as measured by K_(i) values (in nM). The activities(potencies) for the compounds of the invention are determined bymeasuring their K_(i) values. The smaller the K_(i) value, the moreactive is a compound for antagonizing the NK₁ receptor. Compounds of theinvention exhibit a wide range of activities. The NK₁ average K_(i)values for compounds of Formula I generally range from 0.01 nM to about1000 nM, preferably, from about 0.1 nM to about 100 nM, with values offrom about 0.1 nM to about 10 nM being more preferred. Even morepreferred are compounds having average K_(i) values of from 0.1 nM toabout 5 nM for the NK₁ receptor. Especially preferred compounds have NK₁average K_(i) values of from 0.1 nM to about 1 nM. Even more especiallypreferred compounds have NK₁ average K_(i) values of from 0.1 nM toabout 0.3 nM. Compounds 2, 9, 10, 12, 14, 16, 19, 20, 23, 29, 30, 42,and 54 (see Table I above) have K_(i) values, respectively, of 0.12,0.18, 0.1, 0.05, 0.1, 0.13, 0.1, 0.11, 0.12 0.11, 0.54, 0.28, and 0.12nM.

Compounds of the Formula I have a number of utilities. For instance, theinventive compounds can be useful as antagonists of neurokininreceptors, particularly, NK₁ receptors in a mammal, such as a human. Assuch, they may be useful in treating and preventing one or more of avariety of mammalian (human and animal) disease states (physiologicaldisorders, symptoms and diseases) in a patient in need of suchtreatment, wherein the disease states are selected from the groupconsisting of: (1) respiratory diseases (e.g., chronic lung disease,bronchitis, pneumonia, asthma, allergy, cough and bronchospasm), (2)inflammatory diseases (e.g., arthritis and psoriasis), (3) skindisorders (e.g., atopic dermatitis and contact dermatitis), (4)ophthalmologic disorders (e.g., retinitis, ocular hypertension andcataracts), (5) central nervous system conditions, such as depressions(e.g., neurotic depression), anxieties (e.g., general anxiety, socialanxiety and panic anxiety disorders), phobias (e.g., social phobia), andbipolar disorder, (6) addictions (e.g., alcohol dependence andpsychoactive substance abuse), (7) epilepsy, (8) nociception, (9)psychosis, (10) schizophrenia, (11) Alzheimer's disease, (12) AIDsrelated dementia, (13) Towne's disease, (14) stress related disorders(e.g., post traumatic stress disorder), (15) obsessive/compulsivedisorders, (16) eating disorders (e.g., bulimia, anorexia nervosa andbinge eating), (17) sleep disorders, (18) mania, (19) premenstrualsyndrome, (20) gastrointestinal disorders (e.g., irritable bowelsyndrome, Crohn's disease, colitis, and emesis), (21) atherosclerosis,(22) fibrosing disorders (e.g., pulmonary fibrosis), (23) obesity, (24)Type II diabetes, (25) pain related disorders (e.g., headaches, such asmigraines, neuropathic pain, post-operative pain, and chronic painsyndromes), (26) bladder and genitourinary disorders (e.g., interstitialcystitis and urinary incontinence), (27) emesis (e.g.,chemotherapy-induced (e.g., induced by cisplatin, doxorubicin, andtaxane), radiation-induced, motion sickness, ethanol-induced, and postoperative nausea and vomiting), and (28) nausea. Preferably, theinventive compounds can be useful in treating and preventing one of thefollowing mammalian (e.g., human) disease states in a patient in need ofsuch treatment: respiratory diseases (e.g., cough), depression, anxiety,phobia, and bipolar disorder, alcohol dependence, psychoactive substanceabuse, nociception, psychosis, schizophrenia, stress related disorders,obsessive/compulsive disorder, bulimia, anorexia nervosa and bingeeating, sleep disorders, mania, premenstrual syndrome, gastrointestinaldisorders, obesity, pain related disorders, bladder disorders,genitourinary disorders, emesis and nausea. In particular, the compoundsaccording to Formula I are useful for treating disease states related tomicrovascular leakage and mucus secretion. Consequently, the compoundsof the invention are especially useful in the treatment and preventionof asthma, emesis, nausea, depressions, anxieties, cough and painrelated disorders, more especially, emesis, depression, anxiety andcough.

In another aspect, the invention relates to pharmaceutical compositionscomprising at least one compound (e.g., one to three compounds,preferably, one compound) represented by Formula I and at least onepharmaceutically acceptable excipient or carrier. The invention alsorelates to the use of such pharmaceutical compositions in the treatmentof mammalian (e.g., human) disease states, such as those listed above.

In still another aspect of the invention, a method is provided forantagonizing the effects of a Substance P at a neurokinin-1 receptorsite or for the blockade of one or more neurokinin-1 receptors in amammal (i.e., a patient, e.g., a human) in need of such treatment,comprising administering to the mammal an effective amount of at leastone (e.g., one) compound according to Formula I.

In another aspect of the invention, an effective amount of one or moreof the inventive NK₁ receptor antagonists may be combined with aneffective amount of one or more anti-depressant agents and/or one ormore anti-anxiety agents (e.g., gepirone, gepirone hydrochloride,nefazodone, and nefazodone hydrochloride (e.g., Serzone®) to treatdepression and/or anxiety. U.S. Pat. No. 6,117,855 (2000), thedisclosure of which is incorporated herein by reference, discloses amethod for treating or preventing depression or anxiety with acombination therapy of a specific NK₁ receptor antagonist together withan anti-depressant and/or anti-anxiety agent. Thus, anti-depressantand/or anti-anxiety agents, such as those disclosed in U.S. Pat. No.6,117,855 (2000), can be combined with one or more (e.g., one) compoundsof the Formula I to treat depression and/or anxiety disease states in amammal, preferably, a human.

In still another aspect of the invention, an effective amount of one ormore (e.g., one) of the inventive NK₁ receptor antagonists may becombined with an effective amount of one or more (e.g., one) selectiveserotonin reuptake inhibitors (“SSRIs”) to treat a variety of mammaliandisease states, such as those described above. SSRIs alter the synapticavailability of serotonin through their inhibition of presynapticreaccumulation of neuronally released serotonin. U.S. Pat. No. 6,162,805(2000), the disclosure of which is incorporated herein by reference,discloses a method for treating obesity with a combination therapy of aNK₁ receptor antagonist and an SSRI. One or more inventive compound(s)of the Formula I can be combined together with an SSRI(s) in a singlepharmaceutical composition, or it can be administered simultaneously,concurrently or sequentially with an SSRI. This combination may beuseful in the treatment and prevention of obesity or another of theabove-identified human and animal disease states. In particular, aneffective amount of at least one (e.g., one) compound having the FormulaI, alone or together with an effective amount of at least one (e.g.,one) selective serotonin reuptake inhibitor, can be useful in thetreatment and prevention of depression, and/or anxiety.

Numerous chemical substances are known to alter the synapticavailability of serotonin through their inhibition of presynapticreaccumulation of neuronally released serotonin. Representative SSRIsinclude, without limitation, the following: fluoxetine, fluoxetinehydrochloride (e.g., Prozac®), fluvoxamine, fluvoxamine maleate (e.g.Luvox®), paroxetine, paroxetine hydrochloride (e.g., Paxil®),sertraline, sertraline hydrochloride (e.g., Zoloft®), citalopram,citalopram hydrobromide (e.g., Celexa™), duloxetine, duloxetinehydrochloride, venlafaxine, and venlafaxine hydrochloride (e.g.,Effexor®). Further SSRIs include those disclosed in U.S. Pat. No.6,162,805 (2000). Other compounds can readily be evaluated to determinetheir ability to selectively inhibit serotonin reuptake. Thus, oneaspect of the invention relates to a pharmaceutical compositioncomprising at least one (e.g., one) NK₁ receptor antagonist having theFormula I, at least one (e.g., one) SSRI, and at least onepharmaceutically acceptable excipient or carrier. Another aspect of theinvention relates to a method of treating the above identified mammalian(e.g., human) disease states, the method comprising administering to apatient in need of such treatment an effective amount of apharmaceutical composition comprising at least one (e.g., one) NK₁receptor antagonist having the Formula I in combination with at leastone (e.g., one) SSRI, such as one of those recited above, and at leastone pharmaceutically acceptable excipient or carrier.

In a preferred aspect, the invention relates to a method of treatingdepression and anxiety, the method comprising administering to a patientin need of such treatment an effective amount of at least one (e.g.,one) NK₁ receptor antagonist having the Formula I in combination with atleast one (e.g., one) SSRI, such as one of those described above. Whenan inventive NK₁ receptor antagonist is combined with an SSRI foradministration to a patient in need of such treatment, the two activeingredients can be administered simultaneously, consecutively (one afterthe other within a relatively short period of time), or sequentially(first one and then the other over a period of time). In general, whenthe two active ingredients are administered consecutively orsequentially, the inventive NK₁ receptor antagonist is, preferably,administered before the administration of the SSRI.

It is another embodiment of the invention to treat a patient sufferingfrom multiple ailments with a combination therapy, the therapycomprising administering to a patient (e.g., a mammal, preferably ahuman) in need of such treatment at least one compound of Formula I, andat least one other active ingredient (i.e., drug) used for treating oneor more of the ailments being suffered by the patient. The compounds ofFormula I and the other active ingredients can be administeredsequentially, concurrently and/or simultaneously. The compounds ofFormula I and the other active ingredients can be administeredseparately in any suitable dosage form. Preferably, administration isaccomplished using an oral dosage forms or using a transdermal patches.The compounds of Formula I and the other active ingredients can beformulated together and administered in one combined dosage form.

Thus, the compounds of the invention may be employed alone or incombination with other active agents. Combination therapy includes theadministration of two or more active ingredients to a patient in need oftreatment. In addition to the above described NK₁ receptorantagonist/SSRI combination therapy, the compounds having the Formula Imay be combined with one or more other active agents, such as thefollowing: other types of NK₁ receptor antagonists (e.g., those that aredisclosed in neurokinin receptor antagonist patents cited above),prostanoids, H₁ receptor antagonists, α-adrenergic receptor agonists,dopamine receptor agonists, melanocortin receptor agonists, endothelinreceptor antagonists, endothelin converting enzyme inhibitors,angiotensin II receptor antagonists, angiotensin converting enzymeinhibitors, neutral metalloendopeptidase inhibitors, ET_(A) antagonists,renin inhibitors, serotonin 5-HT₃ receptor antagonists (e.g.,ondansetron, ondansetron hydrochloride (e.g., Zolfran®), palonosetron,granisetron, and granisetron hydrochloride (e.g., Kytril®), serotonin5-HT₂c receptor agonists, nociceptin receptor agonists, glucocorticoids(e.g., dexamethasone), rho kinase inhibitors, potassium channelmodulators and/or inhibitors of multi-drug resistance protein 5.

Particularly useful therapeutic agents for combination therapy withcompounds of the invention are the following: prostanoids, such asprostaglandin E₁; α-adrenergic agonists, such as phentolamine mesylate;dopamine receptor agonists, such as apomorphine; angiotensin IIantagonists, such as losartan, irbesartan, valsartan and candesartan;ET_(A) antagonists, such as bosentan and ABT-627; serotonin 5-HT₃receptor antagonists, such as ondansetron; and glucocorticoids, such asdexamethasone. In preferred embodiments of the invention, the inventivecompounds can be combined with: other types of NK₁ receptor antagonists,SSRIs, dopamine receptor agonists, serotonin 5-HT₃ receptor antagonists,serotonin 5-HT_(2c) receptor agonists, nociceptin receptor agonists,glucocorticoids and/or inhibitors of multi-drug resistance protein 5.

Another embodiment of this invention is directed to a method fortreating a physiological disorder, symptom or disease in a patient inneed of such treatment, comprising administering to the patient aneffective amount of at least one compound of Formula I, and an effectiveamount of at least one active ingredient selected from the groupconsisting of: other NK₁ receptor antagonists, selective serotoninreuptake inhibitors, dopamine receptor agonists, serotonin 5-HT₃receptor antagonists, serotonin 5-HT_(2c) receptor agonists, nociceptinreceptor agonists, glucocorticoids and inhibitors of multidrugresistance protein 5, wherein the physiological disorder, symptom ordisease is selected from the group consisting of: a respiratory disease,depression, anxiety, phobia, bipolar disorder, alcohol dependence,psychoactive substance abuse, nociception, psychosis, schizophrenia,stress related disorder, obsessive/compulsive disorder, bulimia,anorexia nervosa, binge eating, sleep disorder, mania, premenstrualsyndrome, gastrointestinal disorder, obesity, headache, neuropathicpain, post-operative pain, chronic pain syndrome, bladder disorder,genitourinary disorder, cough, emesis and nausea.

Pharmaceutical compositions may contain from about 0.1 to about 99.9weight percent, or from about 5 to about 95 weight percent, or fromabout 20 to about 80 weight percent of active ingredient (compound ofthe Formula I). For preparing pharmaceutical compositions from thecompounds described by this invention, inert, pharmaceuticallyacceptable carriers can be either solid or liquid. Solid formpreparations include powders, tablets, dispersible granules, capsules,cachets and suppositories. The powders and tablets may be comprised offrom about 5 to about 95 percent active ingredient. Suitable solidcarriers are known in the art, e.g. magnesium carbonate, magnesiumstearate, talc, sugar or lactose. Tablets, powders, cachets and capsulescan be used as solid dosage forms suitable for oral administration.Examples of pharmaceutically acceptable carriers and methods ofmanufacture for various compositions may be found in A. Gennaro (ed.),Remington: The Science and Practice of Pharmacy, 20^(th) Edition,(2000), Lippincott Williams & Wilkins, Baltimore, Md., hereinincorporated by reference.

Liquid form preparations include solutions, suspensions and emulsions,for example, water or water-propylene glycol solutions for parenteralinjection or addition of sweeteners and opacifiers for oral solutions,suspensions and emulsions. Liquid form preparations may also includesolutions for intranasal administration.

Aerosol preparations suitable for inhalation may include solutions andsolids in powder form, which may be in combination with apharmaceutically acceptable carrier, such as an inert compressed gas,e.g. nitrogen.

Also included are solid form preparations, which are intended to beconverted, shortly before use, to liquid form preparations for eitheroral or parenteral administration. Such liquid forms include solutions,suspensions and emulsions.

The compounds of the invention may also be deliverable transdermally.The transdermal compositions can take the form of creams, lotions,aerosols and/or emulsions and can be included in a transdermal patch ofthe matrix or reservoir type as are conventional in the art for thispurpose.

Preferably the compound is administered orally.

Preferably, the pharmaceutical preparation is in a unit dosage form. Insuch form, the preparations subdivided into suitably sized unit dosescontaining appropriate quantities of the active component, e.g., aneffective amount to achieve the desired purpose.

The term “pharmaceutical composition” is also intended to encompass boththe bulk composition and individual dosage units, in any of the formsdescribed herein, comprised of more than one (e.g., two)pharmaceutically active agents such as, for example, a compound of thepresent invention and an additional agent selected from the lists of theadditional agents described herein, along with any pharmaceuticallyinactive excipients. The bulk composition and each individual dosageunit can contain fixed amounts of the aforesaid “more than onepharmaceutically active agents”. The term “bulk composition” meansmaterial that has not yet been formed into individual dosage units. Anillustrative dosage unit is an oral dosage unit such as tablets, pillsand the like. Similarly, the herein-described method of treating apatient by administering a pharmaceutical composition of the presentinvention is also intended to encompass the administration of theaforesaid bulk composition and individual dosage units.

The quantity of active compound in a unit dose of preparation may bevaried or adjusted from about 0.01 mg to about 4000 mg, preferably fromabout 0.02 mg to about 1000 mg, more preferably from about 0.3 mg toabout 500 mg, and most preferably from about 0.04 mg to about 250 mgaccording to the particular application.

The actual dosage employed may be varied depending upon the requirementsof the patient and the severity of the condition being treated.Determination of the proper dosage regimen for a particular situation iswithin the skill in the art. For convenience, the total daily dosage maybe divided and administered in portions during the day as required.

The amount and frequency of administration of the compounds of theinvention and/or the pharmaceutically acceptable salts thereof will beregulated according to the judgment of the attending clinicianconsidering such factors as age, condition and size of the patient aswell as severity of the symptoms being treated. A typical recommendeddaily dosage regimen for oral administration can range from about 0.02mg/day to about 2000 mg/day, in two to four divided doses.

The pharmaceutical compositions of the invention may be administeredfrom about 1 to about 5 times per day, or alternatively, as a continuousinfusion. Such administration can be used as a chronic or acute therapy.

The quantity of NK₁ receptor antagonist in combination with a selectiveserotonin reuptake inhibitor (“SSRI”) in a unit dose of preparation maybe from about 10 to about 300 mg of NK₁ receptor antagonist combinedwith from about 10 to about 100 mg of SSRI. In another combination thequantity of NK₁ receptor antagonist in combination with a SSRI in a unitdose of preparation may be from about 50 to about 300 mg of NK₁ receptorantagonist combined with from about 10 to about 100 mg of SSRI. Inanother combination the quantity of NK₁ receptor antagonist incombination with SSRI in a unit dose of preparation may be from about 50to about 300 mg of NK₁ receptor antagonist combined with from about 20to about 50 mg of SSRI.

The actual dosage employed may be varied depending upon the requirementsof the patient and the severity of the condition being treated.Determination of the proper dosage regimen for a particular situation iswithin the skill of the art. For convenience, the total daily dosage maybe divided and administered in portions during the day as required. Uponimprovement of a patient's condition, a maintenance dose of a compound,composition or combination of the invention may be administered, ifnecessary. Subsequently, the dosage or frequency of administration, orboth, may be reduced, as a function of the symptoms, to a level at whichthe improved condition is retained. When the symptoms have beenalleviated to the desired level, treatment should cease. Patients may,however, require intermittent treatment on a long-term basis upon anyrecurrence of disease symptoms.

Specific dosage and treatment regimens for any particular patient may bevaried and will depend upon a variety of factors, including the activityof the specific compound employed, the age, body weight, general healthstatus, sex and diet of the patient, the time of administration, therate of excretion, the specific drug combination, the severity andcourse of the symptoms being treated, the patient's disposition to thecondition being treated and the judgment of the treating physician.Determination of the proper dosage regimen for a particular situation iswithin the skill of the art.

EXAMPLES

The invention disclosed herein is exemplified by the followingpreparations and examples, which should not be construed to limit thescope of the disclosure. Alternative mechanistic pathways and analogousstructures may be apparent to those skilled in the art.

Preparative Example 1

In a 25 mL round-bottomed flask, Compound 42b (0.253 g, 0.42 mmol, 1.0equiv) was taken up in 5 mL of CH₂Cl₂, and the resulting reactionmixture was cooled to 0° C. in an ice bath. Et₃N (0.088 mL, 0.63 mmol,1.5 equiv) followed by 4-chlorobutyryl chloride (0.065 mL, 0.5 mmol, 1.2equiv) was then added to the reaction mixture, which was subsequentlyslowly warmed to room temperature and was stirred for 14 hrs. Theprogress of the reaction was monitored by TLC (60:40 EtOAc/hexane) andMS. Upon completion, the reaction mixture was diluted with CH₂Cl₂,quenched with saturated aqueous NaHCO₃, followed by brine. The organiclayer was dried over Na₂SO₄ and concentrated to give crude Compound 1a(0.3 g), which was used in the next step without further purification.

Electrospray MS [M+1] 724.4.

In a flame-dried 25 mL round-bottomed flask, Compound 1a (0.3 g, 0.4mmol, 1.0 equiv) was taken up in dry THF. To this reaction mixture, 60%NaH (0.025 g, 0.62 mmol, 1.5 equiv) was added, and reaction mixture wasstirred at room temperature for 2 hrs. The progress of the reaction wasmonitored by TLC (60:40 EtOAc/hexane) and MS. Upon completion, thereaction mixture was diluted with EtOAc and quenched with saturatedaqueous NaHCO₃. The organic layer was dried over Na₂SO₄ and concentratedto give Compound 1b (0.25 g), which was used in the next step withoutfurther purification.

Compound 1b (0.25 g, 0.37 mmol, 1.0 equiv) was dissolved in dry MeOH(2.0 mL) and was treated with 20% Pd(OH)₂ (60% wt.) under an inertatmosphere. The reaction mixture was hydrogenated at atmosphericpressure and was monitored by TLC (60:40 EtOAc/hexane). The reaction wascompleted in 45 min, and the reaction mixture was then filtered throughCELITE (diatomaceous earth), washed with EtOAc, and concentrated to givea crude product. Purification was carried out using preparative platechromatography (60/40 EtOAc/hexane) to give Compound 1 (0.10 g, 49%).

Electrospray MS [M+1] 554.3.

HRMS (FAB) calculated for C₂₈H₂₉F₆N₃O₂ (M+1) 554.2242, found 554.2249.

Preparation Example 2

In a 25 ml round-bottomed flask, Compound 42b (0.3264 g, 0.44 mmol, 1.0equiv) was taken up in 5 mL of THF, and the reaction mixture was cooledto 0° C. in an ice bath. Et₃N (0.073 mL, 0.44 mmol, 1.2 equiv) followedby 2-chloroethyl chloroformate (0.054 mL, 0.44 mmol, 1.2 equiv) was thenadded to the reaction mixture, which was slowly warmed to roomtemperature and stirred for 14 hrs. The progress of the reaction wasmonitored by TLC (40:60 EtOAc/hexane) and MS. The reaction did not go tocompletion, and hence was diluted with EtOAc and quenched with saturatedNaHCO₃ followed by brine. The organic layer was dried over Na₂SO₄ andconcentrated to give (0.3 g) crude product, which was subjected toBIOTAGE chromatography (40:60 EtOAc/hexane) to give Compound 2a (0.125g).

Electrospray MS [M+1] 712.4.

In a flame-dried 25 ml round-bottomed flask, Compound 2a (0.125 g, 0.175mmol, 1.0 equiv) was taken up in dry THF. To this reaction mixture, 60%NaH (0.10 g, 0.26 mmol, 1.5 equiv) was added and reaction mixture wasstirred at room temperature overnight. The progress of the reaction wasmonitored by TLC (40:60 EtOAc/hexane) and MS. Upon completion of thereaction, the reaction mixture was diluted with EtOAc and quenched withsaturated aqueous NaHCO₃. The organic layer was dried over Na₂SO₄ andconcentrated to give Compound 2b (0.11 g), which was used in the nextstep without further purification.

Electrospray MS [M+1] 676.2.

Compound 2b (0.11 g, 0.16 mmol, 1.0 equiv) was dissolved in dry MeOH(2.0 mL) and was treated with 20% Pd(OH)₂ (60% wt.) under an inertatmosphere. The reaction mixture was hydrogenated at atmosphericpressure and the progress of the reaction was monitored by TLC (40:60EtOAc/hexane). The reaction was completed in 45 min, filtered throughCELITE, washed with EtOAc, and concentrated to give a crude product. Thecrude product was purified using preparative plate chromatography (45/55EtOAc/hexane) to give Compound 2 (0.04 g, 45%).

Electrospray MS [M+1] 542.3.

HRMS (FAB) calculated for C₂₆H₂₆F₆N₃O₃(M+1) 542.1897, found 542.1878.

Preparative Example 3 and Example 4

NaBH₄ (60 mg, 1.53 mmol, 8 equiv.) was added in portions to a solutionof Compound 30 (109 mg, 0.19 mmol, 1 equiv.) in absolute ethanol (2 mL)at 0° C. After stirring at 0° C. for 30 minutes, TLC (MeOH/CH₂Cl₂=10%)analysis of the reaction mixture showed only product. The product waspurified by BIOTAGE chromatography (2-10% MeOH in CH₂Cl₂), to provide apure mixture of two diastereomers. The two diastereomers were separatedusing Chiral HPLC (ChialCel OD, IPA/Hexane=10%) to give Example 3, MS[M+1]⁺ 573.1; and Example 4, MS [M+1]⁺ 573.1.

Preparative Example 5

MsCl (0.102 mL, 1.32 mmol) was added to a solution of Compound 26a(0.375 g, 0.528 mmol) and Et₃N (0.368 mL, 2.64 mmol) in CH₂Cl₂ (5.0 mL)at 0° C. The reaction mixture was quenched with water (15.0 mL) after 30minutes and then diluted with CH₂Cl₂ (50 mL). The resulting aqueousphase was extracted with CH₂Cl₂ (3×10 mL). The combined organic layerswere washed with water (10 mL), brine (10 mL), and dried over MgSO₄.After filtration and concentration, the crude mesylate was taken up inDMF (3.0 mL) and treated with KCN (0.344 g, 5.28 mmol). The resultingmixture was heated at 100° C. for 12 hours before it was cooled to roomtemperature. The reaction mixture was diluted with EtOAc (100 mL) andwashed with water (3×15 mL). The organic layer was then washed withbrine (25 mL), and dried over MgSO₄. After filtration and concentration,the crude product was purified by BIOTAGE chromatography (hexane/EtOAc,v/v=7/1) to give Compound 5b (0.14 g, 37% for 2 steps).

A solution of Compound 5b (0.14 g, 0.195 mmol) in TFA (2.5 mL) wasstirred at room temperature for 20 minutes before the solvent wasremoved under reduced pressure. The residue was taken up in EtOAc (50mL) and washed with a NaOH solution (4.0 N, 15 mL). The aqueous phasewas extracted with EtOAc (3×10 mL). The combined organic layers werewashed with water (15 mL), brine (15 mL), and then dried over MgSO₄.After filtration and concentration, the crude product was passed througha short pad of silica gel with EtOAc/MeOH (v/v=10/1) as eluent, toprovide an amine (90 mg) after solvent removal. The amine was taken upin pyridine (1.0 mL) and treated with HC(O)NHNHC(O)H (38.3 mg, 0.435mmol), TMSCI (0.276 mL, 2.175 mmol) and Et₃N (0.152 mL, 1.088 mmol) atroom temperature in a sealed tube. The reaction mixture was then heatedat 100° C. for 2.5 hours before it was cooled down to room temperature.The mixture was then diluted with EtOAc (40 mL) and washed with HCl (10mL, 2.0 N). The resulting aqueous phase was extracted with EtOAc (3×15mL). The combined organic layers were washed with water (15 mL), brine(25 mL), and dried over MgSO₄. After filtration and concentration, thecrude product was purified using BIOTAGE chromatography (EtOAc/MeOH,v/v=10/1) to give Compound 5c (40 mg, 31% for 2 steps).

Compound 5c (40 mg, 0.0595 mmol) in EtOH (2.0 mL) was treated at roomtemperature with Pd(OH)₂/C (8 mg, 10 wt %) and was hydrogenated using aH₂ balloon for 30 minutes. The reaction mixture was filtered through ashort pad of CELITE and the residue was washed with EtOH (15 mL).Solvent was removed under reduced pressure, and the crude product waspurified using preparative TLC (EtOAc/MeOH, v/v=40/1) to give Compound 5(18 mg, 56%, Electrospray MS [M+1]⁺ 538.1.) and Compound 5d (6 mg, 19%,Electrospray MS [M+1]⁺ 538.1.).

Preparation Example 6

MsCl (75 mL, 0.969 mmol) was added to a solution of Compound 23d (0.248g, 0.388 mmol) and Et₃N (0.27 mL, 1.94 mmol) in CH₂Cl₂ (3.0 mL) at roomtemperature. The reaction was quenched with water (10.0 mL) after 30minutes and diluted with CH₂Cl₂ (30 mL). The aqueous phase was extractedwith CH₂Cl₂ (3×10 mL). The combined organic layers were washed withwater (10 mL), brine (10 mL), and dried over MgSO₄. After filtration andconcentration, the crude mesylate was taken up in anhydrous DMSO (3.0mL) and treated with NaBH₄ (59.0 mg, 1.552 mmol). The reaction mixturewas heated at 85° C. for 48 hours before it was cooled down to roomtemperature. The mixture was then diluted with EtOAc (50 mL) and washedwith aqueous HCl (10 mL, 1.0 M). The resulting aqueous phase wasextracted with EtOAc (3×15 mL). The combined organic layers were washedwith water (3×15 mL), brine (15 mL), and dried over MgSO₄. Afterfiltration and concentration, the crude product was purified usingBIOTAGE chromatography (hexane/EtOAc, v/v=5/1) to give Compound 6a (0.11g, 45% for 2 steps).

A mixture of Compound 6a (0.11 g, 0.176 mmol) and Zn dust (0.114 g, 1.76mmol) in HOAC (1.5 mL) was heated at 60° C. for 2 hours. The reactionmixture was cooled down and filtered through a short pad of CELITE andthe residue was washed with EtOH (15 mL). Solvent was removed underreduced pressure and the residue was taken up in EtOAc (25 mL) andwashed with a NaOH solution (4.0 N, 10 mL). The resulting aqueous phasewas extracted with EtOAc (3×10 mL). The combined organic layers werewashed with water (15 mL), brine (15 mL), and dried over MgSO₄. Afterfiltration and concentration, the crude amine (67.1 mg, 0.113 mmol) wastaken up in pyridine (1.0 mL) and treated with HC(O)NHNHC(O)H (29.8 mg,0.339 mmol), TMSCI (0.214 mL, 1.69 mmol) and Et₃N (0.118 mL, 0.847 mmol)at room temperature in a sealed tube. The mixture was then heated at100° C. for 2.5 hours before it was cooled down to room temperature. Themixture was then diluted with EtOAc (40 mL) and washed with HCl (10 mL,2.0 N). The resulting aqueous phase was extracted with EtOAc (3×15 mL).The combined organic layers were washed with water (15 mL), brine (15mL), and dried over MgSO₄. After filtration and concentration, the crudeproduct was purified using BIOTAGE chromatography (EtOAc/MeOH, v/v=20/1)to give Compound 6b (37 mg, 33% for 2 steps).

Compound 6b (36.5 mg, 0.0565 mmol) in EtOH (2.0 mL) was treated at roomtemperature with Pd(OH)₂/C (7.3 mg, 10 wt %) and was hydrogenated usinga H₂ balloon for 30 minutes. The reaction mixture was filtered through ashort pad of CELITE and the residue was washed with EtOH (15 mL).Solvent was removed under reduced pressure and the crude product waspurified using preparative TLC (EtOAc/MeOH/Et₃N, v/v/v=40/1/0.1) to giveCompound 6 (20 mg, 69%). Electrospray MS [M+1]⁺ 513.1.

Preparation Example 7

Dess-Martin Periodinane (0.114 g, 0.268 mmol) was added to a mixture ofCompound 12a (70.5 mg, 0.107 mmol) and NaHCO₃ (0.112 g, 1.34 mmol) inCH₂Cl₂ (3.0 mL) at room temperature. The reaction was stirred for 1 hourbefore it was diluted with the addition of EtOAc (30 mL) and water (10mL). The organic phase was washed with saturated Na₂S₂O₃ solution (3×10mL). The combined aqueous phases were extracted with EtOAc (3×10 mL).The combined organic layers were washed with a NaOH solution (10 mL, 1.0N), water (10 mL), brine (15 mL), and dried over MgSO₄. After filtrationand concentration, the crude aldehyde (70.5 mg, 0.107 mmol) wasdissolved in EtOH (3.0 mL) and treated with HONH₂HCl (74.4 mg, 1.07mmol) and NaOAc (43.9 mg, 0.535 mmol) at room temperature. The reactionmixture was stirred for 12 hours before it was diluted with EtOAc (20mL) and washed with aqueous NaHCO₃ (10 mL). The aqueous phase wasextracted with EtOAc (3×10 mL). The combined organic layers were washedwith water (10 mL), brine (10 mL), and dried over MgSO₄. Afterfiltration and concentration, the crude oxime was obtained (63 mg, 0.093mmol) which was taken up in benzene (2.0 mL) and treated with1,1′-oxalyldiimidazole (35.4 mg, 0.186 mmol). The reaction mixture washeated at 80° C. for 3 hours before it was cooled down to roomtemperature and diluted with EtOAc (20 mL) and washed with aqueous HCl(0.5 N, 5 mL). The aqueous phase was extracted with EtOAc (3×10 mL). Thecombined organic layers were washed with water (10 mL), brine (10 mL),and dried over MgSO₄. After filtration and concentration, the crudeproduct was purified using BIOTAGE chromatography (EtOAc) to giveCompound 7a (39 mg, 55% for 3 steps).

Compound 7a (39 mg, 0.059 mmol) in EtOH (2.5 mL) was treated at roomtemperature with Pd(OH)₂/C (7.8 mg, 10 wt %) and was hydrogenated usinga H₂ balloon for 30 minutes. The reaction solution was filtered througha short pad of CELITE and the residue was washed with EtOH (15 mL).Solvent was removed under reduced pressure and the crude product waspurified using preparative TLC (EtOAc/Et₃N, v/v=100/0.1) to giveCompound 7 (12.2 mg, 40%). Electrospray MS [M+1]⁺ 524.3.

Preparation Example 8

Dess-Martin Periodinane (0.325 g, 0.767 mmol) was added to a mixture ofCompound 12a (0.202 g, 0.306 mmol) and NaHCO₃ (0.322 g, 3.83 mmol) inCH₂Cl₂ (5.0 mL) at room temperature. The reaction was stirred for 1 hourbefore it was diluted with EtOAc (50 mL) and water (10 mL). The organicphase was washed with saturated Na₂S₂O₃ solution (3×15 mL). The combinedaqueous phases were extracted with EtOAc (3×15 mL). The combined organiclayers were washed with NaOH solution (15 mL, 1.0 N), water (10 mL),brine (15 mL), and dried over MgSO₄. After filtration and concentration,the crude aldehyde (0.202 g) was taken up in tert-butanol (4.0 mL) andwater (1.0 mL) and treated with NaH₂PO₄H₂O (84.4 mg, 0.612 mmol), NaClO₂(96.8 mg, 1.07 mmol) and 2-methyl-2-butene (0.227 mL, 2.14 mmol)successively. The reaction mixture was stirred for 2 hours and thendiluted with EtOAc (30 mL) and washed with aqueous NH₄Cl. The resultingaqueous phase was extracted with EtOAc (3×10 mL). The combined organiclayers were washed with water (10 mL), brine (10 mL), and dried overMgSO₄. After filtration and concentration, the crude acid was dissolvedin benzene (4.0 mL) and MeOH (1.0 mL). The resulting solution wastreated with TMSCHN₂ (0.306 mL, 0.612 mmol) at room temperature andstirred for 20 minutes. Solvent was removed under reduced pressure andthe crude product was purified using BIOTAGE chromatography(hexane/EtOAc, v/v=5/1 to 1/3) to give Compound 8a (62 mg, 29% for 3steps).

Compound 8a (62 mg, 0.090 mmol) in EtOH (3.0 mL) was treated at roomtemperature with Pd(OH)₂/C (12.4 mg, 10 wt %) and was hydrogenated usinga H₂ balloon for 30 minutes. The reaction mixture was filtered through ashort pad of CELITE and the residue was washed with EtOH (15 mL).Solvent was removed under reduced pressure and the crude product waspurified using BIOTAGE chromatography (EtOAc/MeOH, v/v=6/1) to giveCompound 8 (42 mg, 84%). Electrospray MS [M+1]⁺ 557.3.

Preparation Example 9

In a 25 ml round-bottomed flask, Compound 42b (0.21 g, 0.35 mmol, 1.0equiv) was taken up in 2 mL of toluene. 3-chloropropionyl chloride(0.037 mL, 0.38 mmol, 1.1 equiv) was then added to the reaction mixture,which was stirred at room temperature for five hrs. The progress of thereaction was monitored by TLC (60:40 EtOAc/hexane) and MS, which showedsome starting material was still present. The reaction mixture was thusheated to 80° C. Upon completion of the reaction after a further hour ofheating, the mixture was concentrated to give crude product Compound 9a(0.2 g), which was used in the next step without further purification.

In a flame-dried 25 ml round-bottomed flask, Compound 9a (0.2 g, 0.287mmol, 1.0 equiv) was taken up in a 0.5 M solution of dry CH₂Cl₂/DMF(4/1) ratio (4.59 mL/1.15 mL). To this mixture a 0.5 M solution of 60%NaH (0.012 g, 0.316 mmol, 1.1 equiv) in dry CH₂Cl₂/DMF (4/1 ratio; 5.06mL/1.26 mL) was very slowly added using a syringe pump over a period of3.5 hrs and the reaction mixture was stirred at room temperatureovernight. The progress of the reaction was monitored by TLC (40:60EtOAc/hexane) and MS. The reaction went to 60% completion, and was thendiluted with CH₂Cl₂ and quenched with saturated aqueous NH₄Cl. Theorganic layer was dried over Na₂SO₄ and concentrated to give crudeproduct (0.18 g), which was purified using BIOTAGE chromatography (30/70EtOAc/hexane) to give Compound 9b (0.125 g).

Electrospray MS [M+1] 660.2.

Compound 9b (0.125 g, 0.189 mmol, 1.0 equiv) was dissolved in dry MeOH(1.0 mL) and was treated with 20% Pd(OH)₂ (60% wt.) under an inertatmosphere. The reaction mixture was hydrogenated at atmosphericpressure and the progress of the reaction was monitored by TLC (60:40EtOAc/hexane). The reaction was completed in 20 min, and the reactionmixture was filtered through CELITE, washed using EtOAc, andconcentrated to give crude product. Purification was carried out usingprep plate chromatography (45/55 EtOAc/hexane) to give Compound 9 (0.071g, 71%).

Electrospray MS [M+1] 526.3.

HRMS (FAB) calculated for C₂₆H₂₆F₆N₃O₂ (M+1) 526.1932, found 526.1929.

Preparative Example 10

A solution of Compound 8 (35 mg, 0.063 mmol) in ammonia methanolsolution (3.0 mL, 7.0 M) in a Parr bomb was heated at 80° C. for 5 days.The system was cooled to room temperature and solvent was removed underreduced pressure. The crude product was purified using BIOTAGEchromatography (EtOAc/MeOH, v/v=10/1) to give Compound 10 (26.8 mg,79%). Electrospray MS [M+1]⁺ 542.1.

Preparative Example 11

A solution of methylmagnesium bromide in tert-butylether (0.42 mL, 1.0M,0.42 mmol, 6.2 equiv.) was syringed into a solution of Compound 30b (48mg, 0.068 mmol, 1.0 equiv.) in anhydrous THF (1 mL) at 0° C. Thereaction mixture was then warmed up to room temperature. After TLC(EtOAc eluent) showed that the reaction was complete, the reactionmixture was diluted with ether and washed with saturated aqueous NH₄Clsolution. The combined organic layers were dried over MgSO₄, filteredand concentrated to give crude product, Compound 11a, which was used inthe next step without purification.

Using the same procedure as that of Example 31, Step 6, the crudeCompound 11a was hydrogenated to give pure Example 30b (yield 52.6% fromCompound 11). MS [M+1]⁺ 587.1.

Preparative Example 12

HC(O)NHNHC(O)H (0.28 g, 3.18 mmol), TMSCI (2.0 mL, 15.9 mmol) and Et₃N(1.1 mL, 7.95 mmol) were added successively to a solution of Compound23d (0.647 g, 1.06 mmol) in pyridine (5.0 mL) at room temperature in asealed tube. The mixture was then heated at 100° C. for 2.5 hours beforeit was cooled down to room temperature. The mixture was then dilutedwith EtOAc (100 mL) and washed with HCl (35 mL, 2.0 N). The aqueousphase was extracted with EtOAc (3×25 mL), and the combined organiclayers were washed with water (15 mL), brine (25 mL), and dried overMgSO₄. After filtration and concentration, the crude product waspurified using BIOTAGE chromatography (EtOAc/MeOH, v/v=5/1) to giveCompound 12a (0.48 g, 68%).

Compound 12a (32.6 mg, 0.049 mmol) in EtOH (2.0 mL) was treated at roomtemperature with Pd(OH)₂/C (6.5 mg, 10 wt %) and was hydrogenated usinga H₂ balloon for 30 minutes. The reaction mixture was then filteredthrough a short pad of CELITE and the residue was washed with EtOH (15mL). The solvent was removed under reduced pressure and the crudeproduct was purified using BIOTAGE chromatography (EtOAc/MeOH eluent,v/v=6/1) to give Compound 12 (17.2 mg, 66%). Electrospray MS [M+1]⁺529.1.

Preparative Example 13 and 14

HC(O)NHNHC(O)H (67.1 mg, 0.762 mmol), TMSCI (0.484 mL, 3.81 mmol) andEt₃N (0.266 mL, 1.905 mmol) were added successively to a solution ofCompound 26a (0.155 g, 0.254 mmol) in pyridine (2.0 mL) at roomtemperature in a sealed tube. The mixture was then heated at 100° C. for2.5 hours before it was cooled down to room temperature. The mixture wasdiluted with EtOAc (40 mL) and washed with HCl (15 mL, 2.0 N). Theaqueous phase was extracted with EtOAc (3×15 mL). The combined organiclayers were washed with water (15 mL), brine (25 mL), and dried overMgSO₄. After filtration and concentration, the crude product waspurified using BIOTAGE chromatography (EtOAc/MeOH, v/v=10/1) eluent togive Compound 14a (0.129 g, 75%).

Compound 14a (129 mg, 0.19 mmol) in EtOH (4.0 mL) was treated at roomtemperature with Pd(OH)₂/C (25.8 mg, 10 wt %) and hydrogenated using aH₂ balloon for 30 minutes. The reaction mixture was filtered through ashort pad of CELITE and the residue was washed with EtOH (15 mL).Solvent was removed under reduced pressure and the crude product waspurified using preparative TLC (EtOAc/Et₃N, v/v=100/0.1) to giveCompound 13 (36 mg, 35%, Electrospray MS [M+1]⁺ 543.1.) and Compound 14(30 mg, 29%, Electrospray MS [M+1]⁺ 543.1.).

Preparative Example 15

Dess-Martin Periodinane (57.7 mg, 0.136 mmol) was added to a mixture ofCompound 23 g (46 mg, 0.0678 mmol) and NaHCO₃ (57 mg, 0.678 mmol) inCH₂Cl₂ (2.5 mL) at room temperature. The reaction mixture was stirredfor 1 hour before it was diluted with EtOAc (20 mL) and water (10 mL).The organic phase was washed with saturated Na₂S₂O₃ solution (3×10 mL).The combined aqueous phases were extracted with EtOAc (3×10 mL). Thecombined organic layers were washed with NaOH solution (10 mL, 1.0 N),water (10 mL), brine (15 mL), and dried over MgSO₄. After filtration andconcentration, the crude aldehyde (46 mg, 0.0679 mmol) was taken up inClCH₂CH₂Cl (1.0 mL) and treated with 4A molecular sieves (15 mg) andpara-methoxybenzyl amine (26.7 μl, 0.204 mmol), followed with additionof NaBH(OAc)₃ (86.4 mg, 0.408 mmol). The resulting reaction mixture wasstirred at room temperature for 12 hours. The system was then dilutedwith EtOAc (20 mL) and washed with aqueous NaHCO₃ (10 mL). The aqueousphase was extracted with EtOAc (3×10 mL). The combined organic layerswere washed with water (10 mL), brine (10 mL), and dried over MgSO₄.After filtration and concentration, the crude product was purified usingBIOTAGE chromatography (hexane/EtOAc, v/v=2/3) to give Compound 15a (38mg, 70% for 2 steps).

A mixture of Compound 15a (46.6 mg, 0.0584 mmol), Pd/C (46.6 mg, 10 wt%), and NH₄CO₂H (36.8 mg, 0.584 mmol) in MeOH (2.0 mL) was heated atreflux for 5 hours. The mixture was cooled to room temperature andfiltered through a short pad of CELITE, and the residue was washed withEtOH (15 mL). Solvent was removed under reduced pressure to give a crudeproduct, which was taken up with EtOAc (20 mL) and washed with aqueousNaHCO₃ (10 mL). The aqueous phase was extracted with EtOAc (3×10 mL).The combined organic layers were washed with water (10 mL), brine (10mL), and dried over MgSO₄. After filtration and concentration, the crudeproduct was purified using preparative TLC (MeOH/EtOAc, v/v=1/10) togive Compound 15b (18 mg, 57%).

MsCl (2.5 μL, 0.0324 mmol) was added to a solution of Compound 15b (8.8mg, 0.0162 mmol) and Et₃N (5.4 μL, 0.0388 mmol) in CH₂Cl₂ (1.0 mL) at 0°C. The reaction was quenched with water (5.0 mL) in 30 minutes anddiluted with EtOAc (15 mL). The aqueous phase was extracted with EtOAc(3×10 mL). The combined organic layers were washed with water (10 mL),brine (10 mL), and dried over MgSO₄. After filtration and concentration,the crude product was purified using preparative TLC (hexane/EtOAc,v/v=1/5) to give Compound 15 (7.2 mg, 72%). Electrospray MS [M+1]⁺622.3.

Preparative Example 16

Using the same procedure as that of Example 30, Step 1, Compound 16a wasprepared using ethylamine in the place of N,N-dimethylaminehydrochloride salt, and without using diisopropyl ethyl amine. The crudeproduct was used in the next step without purification.

Using the same procedure as that of Example 31, Step 6, the crudeCompound 16a was hydrogenated to give pure Example 16 (yield 70.5% fromCompound 16). MS [M+1]⁺ 600.1.

Preparative Example 17

A solution of Compound 31 h (46.3 mg, 0.066 mmol, 1.0 equiv.) inanhydrous dichloromethane (1 mL) was cooled to 0° C. To this solutionwas added sequentially DMAP (8 mg, 0.066 mmol, 1.0 equiv.), and ethanol(36 μL). The reaction mixture was allowed to warm up to roomtemperature, and then concentrated to dryness. The residue was taken upinto EtOAc and washed with saturated aqueous NaHCO₃ solution. Theorganic layer was dried over Na₂SO₄, filtered and concentrated to givethe crude product, Compound 17a, which was used in the next step withoutpurification.

Using the same procedure as that of Example 31, Step 6, the crudeCompound 17a was hydrogenated to give pure 17 (yield 46% from Compound31 h). MS [M+1]⁺ 601.1.

Preparative Example 18

Compound 19 (10 mg, 0.0175 mmol) in EtOH (1.5 mL) was treated withHONH₂HCl (12.2 mg, 0.175 mmol) and NaOAc (7.2 mg, 0.0876 mmol) at roomtemperature. The reaction mixture was then stirred at 60° C. for 12hours. The mixture was diluted with EtOAc (20 mL) and washed withaqueous NaHCO₃. The aqueous phase was extracted with EtOAc (3×10 mL).The combined organic layers were washed with water (10 mL), brine (10mL), and dried over MgSO₄. After filtration and concentration, the crudeproduct was purified by preparative TLC (hexane/EtOAc, v/v=2/3) to giveCompound 18 (10 mg, 98%). Electrospray MS [M+1]⁺ 586.1.

Preparative Example 19

Dess-Martin Periodinane (0.252 g, 0.595 mmol) was added to a mixture ofCompound 23h (0.202 g, 0.297 mmol) and NaHCO₃ (0.25 g, 2.97 mmol) inCH₂Cl₂ (4.0 mL) at room temperature. The reaction mixture was stirredfor 1 hour before it was diluted with EtOAc (50 mL) and water (10 mL).The organic phase was washed with a saturated Na₂S₂O₃ solution (3×15mL). The combined aqueous phases were extracted with EtOAc (3×15 mL).The combined organic layers were washed with NaOH solution (15 mL, 1.0N), water (10 mL), brine (15 mL), and dried over MgSO₄. After filtrationand concentration, the crude aldehyde (0.202 g) was taken up inanhydrous THF (4.0 mL) and was treated with CH₃MgBr (1.19 mL, 1.19 mmol,1.0 M in THF) at −78° C. The reaction temperature was slowly increasedto room temperature and the reaction was quenched in 2 hours by the slowaddition of saturated aqueous NH₄Cl solution (10 mL). The reactionmixture was then diluted with EtOAc (50 mL) and neutralized with 0.5 NHCl until the aqueous phase was slightly acidic. The aqueous phase wasextracted with EtOAc (3×15 mL). The combined organic layers were washedwith water (10 mL), brine (10 mL), and dried over MgSO₄. Afterfiltration and concentration, the crude secondary alcohol (0.21 g) wastaken up in CH₂Cl₂ (5.0 mL) and treated with Dess-Martin Periodinane(0.379 g, 0.894 mmol) and NaHCO₃ (0.375 g, 4.47 mmol) at roomtemperature. The reaction mixture was stirred for 1 hour before it wasdiluted with EtOAc (50 mL) and water (10 mL). The organic phase waswashed with saturated Na₂S₂O₃ solution (3×15 mL). The combined aqueousphases were extracted with EtOAc (3×15 mL). The combined organic layerswere washed with aqueous NaOH solution (15 mL, 1.0 N), water (10 mL),brine (15 mL), and dried over MgSO₄. After filtration and concentration,the crude produce was purified using BIOTAGE chromatography(hexane/EtOAc, v/v=1/1) to give Compound 19a (90 mg, 43% for 3 steps).

Compound 19a (57.4 mg, 0.0816 mmol) in EtOH (3.0 mL) was treated at roomtemperature with Pd(OH)₂/C (11.5 mg, 10 wt %) and was hydrogenated usinga H₂ balloon for 30 minutes. The reaction mixture was filtered through ashort pad of CELITE and the residue was washed with EtOH (15 mL).Solvent was removed under reduced pressure and the crude product waspurified using BIOTAGE chromatography (hexane/EtOAc, v/v=2/3) to giveCompound 19 (41 mg, 88%). Electrospray MS [M+1]⁺ 571.1.

Preparative Example 20

NaBH(OAc)₃ (81.4 mg, 0.384 mmol) was added at room temperature to asolution of Compound 26b (79.9 mg, 0.128 mmol), CHOCO₂Et (37.8 μl, 0.192mmol, 45-50% in toluene), and 4 Å molecular sieves (30 mg) in ClCH₂CH₂Cl(1.0 mL). The reaction mixture was stirred for 12 hours before it wasdiluted with EtOAc (20 mL) and washed with aqueous NaHCO₃ (10 mL). Theaqueous phase was extracted with EtOAc (3×10 mL). The combined organiclayers were washed with water (10 mL), brine (10 mL), and dried overMgSO₄. After filtration and concentration, the crude product (91 mg,0.128 mmol) was taken up in ClCH₂CH₂Cl (0.5 mL) and treated withTMSN═C═O (2.5 mL). The reaction mixture was heated at 70° C. for 72hours before the solvent was removed under reduced pressure. The crudeproduct was purified using BIOTAGE chromatography (hexane/EtOAc,v/v=1/1) to give a mixture of Compound 20a and 20b, which was furtherpurified by OD chiral HPLC to give pure Compound 20a (30 mg, 33%) andCompound 20b (25 mg, 28%).

Compound 20a (23 mg, 0.0325 mmol) in EtOH (2.0 mL) was treated at roomtemperature with Pd(OH)₂/C (4.6 mg, 10 wt %) and was hydrogenated usinga H₂ balloon for 30 minutes. The reaction solution was filtered througha short pad of CELITE and the residue was washed with EtOH (15 mL).Solvent was removed under reduced pressure and the crude product waspurified using BIOTAGE chromatography (hexane/EtOAc, v/v=1/3 to 1/9) togive Compound 20 (14.3 mg, 77%). Electrospray MS [M+1]⁺ 574.3

Preparative Example 21 and 22

Compound 21a (1.0 g, 1.4 mmol, 1.0 equiv) was dissolved in CH₂Cl₂ (16mL) and the solution was cooled to 0° C. Diisopropylamine (0.54 g, 4.2mmol, 3.0 equiv.) was added to the reaction mixture, followed by PYBOP(0.88 g, 1.7 mmol, 1.2 equiv.), and the reaction mixture was stirred at0° C. for 5 min., then warmed to room temperature. After 20 min., excessmethyl amine (7.0 mL, 14 mmol, 10.0 equiv.) was added as a 2.0M solutionin THF. The flask became slightly warm, and was stirred at roomtemperature overnight. The progress of the reaction was monitored by TLC(95/5 EtOAc/MeOH eluent). Upon completion of the reaction, the reactionmixture was diluted with H₂O and EtOAc, the organic and aqueous layerswere separated, and the organic layer was washed with brine, dried withNa₂SO₄, and concentrated to give a crude product (1.9 g) as white solid.Purification was carried out using BIOTAGE chromatography (1:1 to 2:1EtOAc/hexane) to give Compound 21 b as a white solid (0.72 g, 72%).

Electrospray MS [M+1] 738.2.

Compound 21c (0.7 g, 0.95 mmol, 1.0 equiv) was dissolved in CH₂Cl₂ (10mL) under a N₂ atmosphere. To the reaction was added excess TFA (2.0 g,19.4 mmol, 20.0 equiv.), and the reaction mixture was stirred at roomtemperature overnight. The progress of the reaction was monitored by TLC(1/1 EtOAc/MeOH eluent), which indicated that some starting material wasstill present. Accordingly, 10.0 equiv. of TFA was added and thereaction mixture was allowed to stir for 3 h. Upon completion of thereaction, the reaction mixture was cooled to 0° C., quenched withsaturated NaHCO₃, and diluted with EtOAc. The organic and aqueous layerswere separated, and the organic layer was washed with brine, dried withNa₂SO₄, and concentrated to give Compound 21d (0.6 g, 99%) as a whitefoam.

Compound 21c (0.24 g, 0.38 mmol, 1.0 equiv) was dissolved in 5 mL ofanhydrous THF under a nitrogen atmosphere. The solution was cooled to 0°C. In a separate round-bottomed flask was combined carbonyldiimidazole(0.15 g, 0.90 mmol, 2.4 equiv) and tert-butyl carbazate (0.1 g, 0.76mmol, 2.0 equiv) in anhydrous THF (2 mL). The solution was allowed tostir for 30 min and added via cannula to the solution of Compound 21cover 1 min. The cannula was rinsed with anhydrous THF (1×0.8 mL). Thereaction mixture was heated to reflux until the starting material wasconsumed. The reaction mixture was then cooled to room temperature andconcentrated under vacuum to afford a colorless foam. The crude mixturewas purified using BIOTAGE chromatography (2%-5% MeOH/CH₂Cl₂) to giveCompound 21d (0.22 g, 74%) as a white solid.

Compound 21d (0.22 g, 0.28 mmol, 1 equiv) was dissolved in 15 mL ofanhydrous CH₂Cl₂ under a nitrogen atmosphere. The solution was cooled to0° C. HCl (1.4 mL, 5.6 mmol, 20 equiv, 4 M solution in dioxane) wasadded and the solution was allowed to warm to room temperature andstirred overnight. The solution was cooled to 0° C. and quenched withsaturated NaHCO₃ (5 mL) solution and diluted with EtOAc. The organic andaqueous layers were separated and the organic layer was washed withbrine (10 mL), and dried over Na₂SO₄. The organic layer was filtered andconcentrated under vacuum to give a white solid. The crude mixture waspurified using BIOTAGE chromatography (5%-8% MeOH/CH₂Cl₂) to giveCompound 21e (0.15 g, 79%) as a white solid.

Compound 21e (0.15 g, 0.22 mmol, 1.0 equiv) was dissolved in anhydrousDMF (1 mL). Foramidine acetate (0.126 g, 1.2 mmol, 5.5 equiv.) followedby acetic acid (0.69 mL, 1.2 mmol, 5.5 equiv.) was added, and thereaction mixture was heated to 80° C. for 30 min. Residual startingmaterial was found by TLC analysis, and accordingly the reaction mixturewas refluxed for an additional 6 h. The progress of the reaction wasmonitored by TLC (9/1 CH₂Cl₂/MeOH eluent). Upon completion of thereaction, the reaction mixture was cooled to room temperature, quenchedwith H₂O, and diluted with EtOAc. The organic and aqueous layers wereseparated and the organic layer was washed with brine, dried withNa₂SO₄, and concentrated to give a crude product (0.131 g) as whitefoam. Purification was carried out using BIOTAGE chromatography(gradient of 100% CH₂Cl₂ to (95:5) MeOH) to give Compound 21f as a whitesolid (0.11 g, 72%).

Electrospray MS [M+1] 706.4.

Compound 21f (0.02 g, 0.028 mmol, 1.0 equiv.) was dissolved in dry MeOH(1.0 mL) and was treated with 10% Pd/C (40% wt.) followed by ammoniumformate (0.09 g, 0.14 mmol, 5.0 equiv.) under an inert atmosphere. Thereaction mixture was heated to reflux and was monitored by TLC (9/1CH₂Cl₂/MeOH eluent). The reaction was completed in 1 hr. The reactionmixture was filtered through CELITE, washed using EtOAc, andconcentrated under vacuum. The resulting residue was taken up in EtOAc,and washed with saturated NaHCO₃, followed by brine and H₂O to give acrude product (0.019 g) as solid film. Purification was carried out byBIOTAGE chromatography (gradient of 2% to 6% MeOH/CH₂Cl₂). The de-airedproduct was converted to the HCl salt to give a mixture of Compounds 21and 22 (0.014 g) as a white solid.

HRMS (FAB) calculated for C₂₆H₂₈F₆N₃O₂ (M+1) 572.2096, found 572.2103.

Preparative Example 23

NaBH₄ (2.42 g, 64.1 mmol) was added in 4 portions to a solution ofCompound 23a in MeOH (160 mL) at 0° C. The reaction mixture was stirredfor 4 hours and the reaction temperature was slowly increased to rt. Thereaction was quenched by the slow addition of saturated aqueous NH₄Clsolution (50 mL). The reaction mixture was then diluted with EtOAc (400mL) and neutralized with 0.5 N HCl until the aqueous phase was slightlyacidic. The aqueous phase was extracted with EtOAc (3×100 mL). Thecombined: organic layers were washed with water (100 mL), brine (100mL), and dried over MgSO₄. After filtration and concentration, the crudeproduct was passed through a short pad of silica gel (hexane/EtOAc,v/v=7/1). Solvent was removed under reduced pressure to give Compound23b, 17.4 g (89%) as a light yellow syrup.

TBAF (2.23 mL, 2.23 mmol, 1.0 M in THF) was added dropwise to a mixtureof Compound 23b (9.1 g, 14.89 mmol) and paraformaldehyde (3.85 g) in THF(100 mL) at 0° C. The reaction mixture was stirred at 0° C. for 8 hoursbefore it was quenched with addition of saturated aqueous NH₄Cl solution(50 mL). The reaction mixture was then diluted with EtOAc (250 mL) andthe aqueous phase was extracted with EtOAc (3×50 mL). The combinedorganic layers were washed with water (50 mL), brine (100 mL), and driedover MgSO₄. After filtration and concentration, the crude product waspurified using BIOTAGE (CH₂Cl₂/EtOAc, v/v=100/0.5) to give Compound 23c(6.0 g, 63%) and 23d (2.34 g, 24%).

A mixture of Compound 23c (7.54 g, 11.76 mmol) and Zn dust (7.68 g,117.6 mmol) in HOAc (120 mL) was heated at 60° C. for 2 hours. Thereaction mixture was cooled down and filtered through a short pad ofCELITE and the residue was washed with EtOH (50 mL). Solvent was removedunder reduced pressure and the residue was taken up in EtOAc (250 mL)and washed with NaOH solution (50 mL, 4.0 N). The aqueous phase wasextracted with EtOAc (3×50 mL). The combined organic layers were washedwith water (50 mL), brine (100 mL), and dried over MgSO₄. Afterfiltration and concentration, the crude product was purified usingBIOTAGE chromatography (hexane/EtOAc, v/v=1/3 and EtOAc/MeOH, v/v=10/1)to give Compound 23e (6.4 g, 89%).

BnBr (0.668 mL, 5.58 mmol) was added at rt to a vigorously stirringmixture of Compound 23e (3.1 g, 5.07 mmol) and Bu₄NHSO₄ (0.334 g, 1.014mmol) in THF (20 mL) and aqueous NaOH solution (20 mL, 50 wt %). Thereaction mixture was stirred at room temperature for 12 hours before itwas diluted with EtOAc (250 mL) and washed with water (100 mL). Theaqueous phase was extracted with EtOAc (3×50 mL). The combined organiclayers were washed with water (50 mL), brine (100 mL), and dried overMgSO₄. After filtration and concentration, the crude product waspurified using BIOTAGE chromatography (hexane/EtOAc, v/v=1/3 to 1/7) togive Compound 23f (2.8 g, 79%).

A solution of Compound 23f (2.72 g, 3.88 mmol) and reagent 31c (i.e.,N-ethoxymethylene-hydrazine carboxylic acid methyl ester) (2.83 g, 19.4mmol) in EtOH (15 mL) was heated at 60° C. for 18 hours. The reactionmixture was diluted with MeOH (15 mL) and then treated with NaOCH₃ (7.0mL, 38.8 mmol, 30% in MeOH). The resulting reaction mixture was heatedat 80° C. for 4 hours before it was cooled to room temperature. Thereaction mixture was diluted with EtOAc (200 mL) and aqueous NH₄Clsolution (75 mL). The aqueous phase was extracted with EtOAc (3×50 mL).The combined organic layers were washed with water (50 mL), brine (100mL), and dried over MgSO₄. After filtration and concentration, the crudeproduct was purified using BIOTAGE chromatography (hexane/EtOAc,v/v=2.5/1 to 1/1) to give Compound 23g (2.54 g, 85%).

BCl₃ (3.26 mL, 3.26 mmol, 1.0 M in hexane) was added dropwise to astirring solution of Compound 23g (0.502 g, 0.653 mmol) in CH₂Cl₂ (45mL) at −78° C. The reaction was quenched in 1 hour by the addition ofaqueous NaHCO₃ solution (50 mL) at −78° C. The mixture was diluted withEtOAc (100 mL) and vigorously stirred at room temperature for 2 hours.The aqueous phase was extracted with EtOAc (3×30 mL). The combinedorganic layers were washed with water (50 mL), brine (50 mL), and driedover MgSO₄. After filtration and concentration, the crude product waspurified using BIOTAGE chromatography (hexane/EtOAc, v/v=1/3 to 1/9) togive Compound 23h (0.39 g, 91%).

Compound 23h (100 mg, 0.152 mmol) in EtOH (5.0 mL) was treated at roomtemperature with Pd(OH)₂/C (20 mg, 10 wt %) and was hydrogenated using aH₂ balloon for 30 minutes. The reaction mixture was filtered through ashort pad of CELITE and the residue was washed with EtOH (15 mL).Solvent was removed under reduced pressure and the crude product waspurified using BIOTAGE chromatography (hexane/EtOAc, v/v=1/7) to giveCompound 23 (68 mg, 82%). Electrospray MS [M+1]⁺ 545.1.

Preparative Example 24

A solution of Compound 31g (83.3 mg, 0.12 mmol, 1.0 equiv.) in anhydrousdichloromethane (4 mL) was cooled to −78° C. Then O₃ was bubbled throughthe solution until the solution turned blue. The solution was thenpurged with N₂ to remove excess O₃, and the reaction mixture wasconcentrated to dryness. The resulting residue was then taken up inethanol (2 mL), and treated with sodium borohydride (46 mg, 1.2 mmol, 10equiv.). The reaction mixture was stirred at room temperature until TLC(50% EtOAc/hexanes) showed that the starting material was completelyconsumed. The reaction mixture was then concentrated to dryness. Theresidue was dissolved in absolute ethanol (4 mL) and treated withPd(OH)₂/C (80 mg, 20 wt %, 0.11 mmol, 0.88 equiv.) before hydrogenatingwith a hydrogen balloon. The reaction mixture was stirred at roomtemperature until TLC (5% MeOH/CH₂Cl₂) showed that the starting materialwas completely consumed. The reaction mixture was again concentrated todryness. The residue was taken up into ethyl acetate, washed withsaturated sodium bicarbonate aqueous solution, and the aqueous andorganic layers separated. The aqueous layer was further extracted withethyl acetate. The combined organic layers were dried over anhydrousNa₂SO₄, filtered, concentrated to give the crude product, which waspurified using Prep-TLC (MeOH/CH₂Cl₂=5%) to give pure Compound 24 (42mg, yield 63%). MS [M+1]⁺ 559.1.

Preparative Example 25

To a solution of Compound 31g (83.3 mg, 0.12 mmol, 1.0 equiv.) inabsolute ethanol (3 mL) was added Pd(OH)₂/C (20 mg, 20 wt %, 0.028 mmol,0.88 equiv.) before hydrogenating with a hydrogen balloon. The reactionmixture was stirred at room temperature until TLC (50% EtOAc/hexanes)showed that starting material was completely consumed. The reactionmixture was then concentrated to dryness. The resulting residue wastaken up into ethyl acetate, washed with saturated sodium bicarbonateaqueous solution, and the aqueous and organic layers were separated. Theaqueous layer was further extracted with ethyl acetate. The combinedorganic layers were dried over anhydrous Na₂SO₄, filtered, andconcentrated to give the crude product, which was purified usingPrep-TLC (50% EtOAc/hexanes) to give pure Compound 25 (15 mg, yield84%). MS [M+1]⁺ 557.1.

Preparative Example 26

Et₃N (0.129 mL, 0.93 mmol) was added to a solution of Compound 26a(0.472 g, 0.77 mmol) and Boc₂O (0.168 g, 0.77 mmol) in dioxane (3.0 mL)at room temperature. The resulting solution was stirred for 8 hoursbefore it was diluted with EtOAc (50 mL). The organic phase was washedwith 0.5 N HCl (10 mL). The aqueous phase was extracted with EtOAc (3×15mL). The combined organic layers were washed with water (15 mL), brine(15 mL), and dried over MgSO₄. After filtration and concentration, thecrude product was purified using BIOTAGE chromatography (hexane/EtOAc,v/v=1/1) to give Compound 26b (0.465 g, 85%).

CH₃I (0.372 mL, 5.98 mmol) was added at rt to a vigorously stirringmixture of Compound 26b (0.425 g, 0.598 mmol) and Bu₄NHSO₄ (40.6 mg,0.12 mmol) in THF (5.0 mL) and aqueous NaOH solution (5.0 mL, 50 wt %).The reaction mixture was stirred at room temperature for 12 hours beforeit was diluted with EtOAc (50 mL) and washed with water (15 mL). Theaqueous phase was extracted with EtOAc (3×15 mL). The combined organiclayers were washed with water (15 mL), brine (15 mL), and dried overMgSO₄. After filtration and concentration, the crude product waspurified using BIOTAGE chromatography (hexane/EtOAc, v/v=5/1) to giveCompound 26c (0.345 g, 80%).

A solution of Compound 26c (0.345 g, 0.476 mmol) in TFA (3.0 mL) wasstirred at room temperature for 20 minutes before the solvent wasremoved under reduced pressure. The residue was taken up in EtOAc (50mL) and washed with NaOH solution (4.0 N, 15 mL). The aqueous phase wasextracted with EtOAc (3×10 mL). The combined organic layers were washedwith water (15 mL), brine (15 mL), and dried over MgSO₄. Afterfiltration and concentration, the crude amine (0.29 g, 0.464 mmol) wasdissolved in EtOH (3.0 mL) and treated with reagent 31c (0.4.6 g, 2.78mmol). The resulting solution was heated at 60° C. for 18 hours. Thereaction mixture was diluted with MeOH (3.0 mL) and then treated withNaOCH₃ (0.672 mL, 3.712 mmol, 30% in MeOH). The resulting reactionmixture was heated at 80° C. for 4 hours before it was cooled to roomtemperature. The system was diluted with addition of EtOAc (50 mL) andaqueous NH₄Cl solution (15 mL). The aqueous phase was extracted withEtOAc (3×15 mL). The combined organic layers were washed with water (15mL), brine (15 mL), and dried over MgSO₄. After filtration andconcentration, the crude product was purified using BIOTAGEchromatography (hexane/EtOAc, v/v=1/3) to give a mixture of Compounds26d and 26e (0.275 g, 83% for 3 steps) which were separated with ODchiral HPLC (hexane/isopropanol v/v=95/5) to give pure Compounds 26d and26e.

Compound 26d (38 mg, 0.0548 mmol) in EtOH (3.0 mL) was treated at roomtemperature with Pd(OH)₂/C (7.6 mg, 10 wt %) and was hydrogenated usinga H₂ balloon for 30 minutes. The reaction solution was filtered througha short pad of CELITE and the residue was washed with EtOH (15 mL).Solvent was removed under reduced pressure and the crude product waspurified using BIOTAGE chromatography (hexane/EtOAc, v/v=1/4) to giveCompound 26 (25 mg, 82%). Electrospray MS [M+1]⁺ 559.1.

Preparative Example 27

Compound 26e (41 mg, 0.0592 mmol) in EtOH (3.0 mL) was treated at roomtemperature with Pd(OH)₂/C (8.2 mg, 10 wt %) and was hydrogenated usinga H₂ balloon for 30 minutes. The reaction solution was filtered througha short pad of CELITE and the residue was washed with EtOH (15 mL).Solvent was removed under reduced pressure and the crude product waspurified using BIOTAGE chromatography (hexane/EtOAc, v/v=1/4) to giveCompound 27 (26 mg, 79%). Electrospray MS [M+1]⁺ 559.1.

Preparative Example 28

In a 25 mL round-bottomed flask, Compound 44b (0.2 g, 0.45 mmol, 1.0equiv) was dissolved in DMF (5.0 mL). HATU (0.342 g, 0.90 mmol, 2.0equiv), EDC (0.172 g, 0.90 mmol, 2.0 equiv), and DIEA (0.118 mL, 0.68mmol, 1.5 equiv) were added. The reaction mixture was cooled to 0° C.and Boc-α-methyl alanine (0.109 g, 0.54 mmol, 1.2 equiv) was added. Thereaction mixture was allowed to stir overnight. The reaction mixture wasthen quenched with saturated NaHCO₃ (5 mL), diluted with EtOAc (10 mL),and extracted with EtOAc (2×5 mL). The organic layer was washed withbrine (10 mL), dried over MgSO₄, and concentrated. The resulting residuewas purified by preparative TLC (9/1 hexanes/EtOAc) to give 0.12 g (43%)of Compound 28a.

Compound 28b was prepared by a method similar to that the compound 45c,described below, in which a DCM solution of Compound 28a was reactedwith TFA to remove the Boc protecting group.

In a 10 mL round-bottomed flask, compound 28b (0.050 g, 0.094 mmol, 1.0equiv) was dissolved in toluene (1 mL), and then trimethylorthoformate(0.012 mL, 0.113 mmol, 1.2 equiv) and 1 drop of acetic acid were added.The solution was heated at 60° C. The reaction mixture was allowed tostir for over 48 hours. The reaction mixture was then taken up in EtOAc(5 mL) and washed with saturated NaHCO₃ (5 mL). The organic layer waswashed with brine (5 mL), dried over MgSO₄, and concentrated. The crudeproduct was purified by preparative TLC (EtOAc) to yield 0.010 g ofCompound 28. HRMS calculated for C₂₇H₂₉F₆N₃O₂ (M+H) 542.2242, found542.2222.

Preparative Example 29

A solution of Compound 31h (39 mg, 0.055 mmol, 1.0 equiv.) in anhydrousdichloromethane (1 mL) was cooled to −20° C. Then triethylamine (10 mL,0.069 mmol, 1.25 equiv.) and ethyl chloroformate (6.5 mL, 0.066 mmol,1.2 equiv.) were added. The resulting pale green solution was stirred at−15° C. for 30 minutes. Ammonia gas was bubbled through the solution for20 minutes. TLC (EtOAc) indicated that the reaction was complete. Thereaction mixture was diluted with ethyl acetate, washed sequentiallywith 1 N HCl (1 mL), saturated sodium carbonate aqueous solution, andbrine. The organic layer was dried over Na₂SO₄, filtered, andconcentrated. The resulting residue was dissolved in absolute ethanol (6mL), to which was added Pd(OH)₂/C (17 mg, 20 wt %, 0.024 mmol, 0.43equiv.) before attaching a hydrogen balloon to the reaction flask. Thereaction mixture was stirred at room temperature until TLC (5%MeOH/EtOAc) showed that the starting material was completely consumed.The reaction mixture was concentrated to dryness, and the residue wastaken up into ethyl acetate, washed with saturated sodium bicarbonateaqueous solution, and the organic and aqueous layers were separated. Theaqueous layer was further extracted with ethyl acetate. The combinedorganic layers were dried over anhydrous Na₂SO₄, filtered, andconcentrated to give the crude product, which was purified usingPrep-TLC (5% MeOH/EtOAc) to give pure Example 29 (18 mg, yield 57%). MS[M+1]⁺ 572.1.

Preparative Example 30

To a solution of Compound 31h (450 mg, 0.64 mmol, 1.0 equiv.) inanhydrous DMF (3.5 mL), was added, sequentially, HATU (290.5 mg, 0.764mmol, 1.2 equiv.), N,N-dimethylamine hydrochloride salt (99 mg, 1.01mmol, 1.6 equiv.) and diisopropyl ethylamine (0.50 μL, 2.87 mmol, 4.5equiv.). The resulting orange solution was stirred at room temperatureuntil TLC (5% MeOH/EtOAc) showed that starting material was completelyconsumed. The reaction mixture was poured into dichloromethane (200 mL),washed sequentially with half-saturated citric acid aqueous solution,saturated NaHCO₃, and brine. The organic layer was dried over anhydrousNa₂SO₄, filtered, and concentrated to give the crude product, which waspurified using BIOTAGE chromatography (EtOAc/Hexane=3:1) to giveCompound 30a as a brown solid (208 mg, yield 43.6%).

Methylmagnesium bromide (1.65 mL, 1.0 M in t-butylether, 1.65 mmol, 6.0equiv.) was added dropwise to a solution of Compound 30a (206 mg, 0.275mmol, 1.0 equiv.) in anhydrous THF (3 mL). TLC (EtOAc) showed that thestarting material was totally gone after the reaction mixture wasstirred at room temperature for 30 minutes. The reaction mixture wasthen diluted with ethyl acetate, quenched with a saturated aqueous NH₄Clsolution, and extracted with EtOAc. The combined organic layers weredried over Na₂SO₄, filtered and concentrated to give the crude product,Compound 30b. Compound 30b was used in the next step withoutpurification.

Using the same procedure as that of Example 31, Step 6, the crudeCompound 30b was hydrogenated to give pure Example 30 (150 mg, yield95.6% from Compound 30a). MS [M+1]⁺ 571.1.

Preparative Example 31

Compound 31b (32 mL) was added to a solution of Compound 31a (1.0 g,11.1 mmol, 1.0 equiv.) in triethylorthoformate. The solution was heatedat 88° C. for 36 hours, and then concentrated to dryness under vacuum.The resulting residue was recrystallized from EtOAc, to give Compound31c (0.94 g, yield 58%).

To a solution of Compound 23b (2.5 g, 4.1 mmol) in THF (20 mL) was addedallylmethylcarbonate (0.465 ml, 8.2 mmol), and Pd(PPh₃)₄ (236 mg, 0.205mmol). The reaction vessel was purged three times with nitrogen, andthen the solution was allowed to stir for 16 hours. The solvent was thenremoved and the residue was filtered through a short silica column using20% EtOAC/hexanes as eluent. The filtrate was concentrated and Compounds31d and 31e were separated using prep-HPLC. MS [M+1]⁺ 651.1 for bothcompounds.

A round-bottomed flask was charged with Compound 31d (3.84 g, 5.90 mmol,1.0 equiv.) and glacial acetic acid (20 mL). To the resulting yellowishsolution at 0° C. was added as several small portions of Zinc dust (3.86g, 59.0 mmol, 10 equiv.). The reaction mixture was stirred at roomtemperature for 6 hours until TLC (30% EtOAc/hexane) showed that thestarting material Compound 31d was totally consumed. The reactionmixture was then diluted with ethyl acetate, and passed through a CELITEpad in a funnel. The CELITE pad was thoroughly washed with ethylacetate, and the combined with the filtrate. The filtrate wasconcentrated to provide a crude product, which was purified usingBIOTAGE chromatography (30% EtOAc/hexanes) to give a pure colorless oilproduct, Compound 31f (3 g, yield 81.9%).

To a solution of Compound 31f (33.4 mg, 0.054 mmol, 1.0 equiv.) inethanol (0.4 mL) was treated with reagent 31c (67.5 mg, 0.46 mmol, 5equiv.) and stirred at room temperature overnight. It was then dilutedwith anhydrous methanol (1 mL) and treated with sodium methoxide, thenheated at 88° C. until TLC (EtOAc) showed only product. It wasconcentrated to dryness, and then taken up into ethyl acetate, washedwith saturated sodium bicarbonate solution and the layers wereseparated. The aqueous layer was further extracted with ethyl acetate.The combined organic layer was dried over anhydrous Na₂SO₄, filtered,and concentrated to get the crude product, which was purified viaBIOTAGE chromatography (25-40% EtOAc/hexanes) to get pure compound 31g(22.4 mg, yield >60%).

Compound 31g (306 mg, 0.44 mmol, 1.0 equiv.) was dissolved in anhydrousdichloromethane (5 mL). The resulting colorless solution was cooled to−78° C., then O₃ was bubbled through until the solution turned purple.The solution was then purged with N₂ to remove excess O₃. The solutionwas then concentrated to dryness. The resulting white foam was dissolvedin formic acid (1.5 mL) and treated with hydrogen peroxide (1.5 mL, 30%aqueous solution) to form a white suspension, which was heated to 80° C.overnight. LCMS analysis showed only the product peak. The solvent wasremoved under vacuum, and the residue was dissolved in ethyl acetate andwashed with half saturated Na₂S₂O₃ aqueous solution. The resulting twolayers were separated, and the aqueous layer was further extracted withethyl acetate. The combined organic layers were dried over anhydrousNa₂SO₄, filtered and concentrated to give the Compound 31h (284.2 mg,yield 90.6%). Compound 31h was used in the next step withoutpurification.

To a solution of Compound 31h (104 mg, 0.147 mmol, 1.0 equiv.) inbenzene (4 mL) and methanol (1 mL), was added dropwise a 2.0M solutionof trimethylsilyl diazomethane in hexanes (88 μL, 0.177 mmol, 1.2equiv.). TLC (10% MeOH/CH₂Cl₂) showed that the starting material wasgone completely after stirring the reaction mixture at room temperaturefor 30 minutes. The solvent was removed to give the crude product, whichwas used in the next step without purification.

The crude product from Step 5, Compound 31i, was dissolved in absoluteethanol (4.5 mL). To this solution was added Pd(OH)₂/C (46.7 mg, 20 wt%, 0.067 mmol, 0.45 equiv.), and then the reaction mixture washydrogenated with a hydrogen balloon. The hydrogenation reaction wasstopped when TLC (10% MeOH/CH₂Cl₂) showed that the starting material wasconsumed. The diluted reaction mixture was carefully passed through aCELITE packed funnel, and the CELITE pad was washed thoroughly withmethanol. The filtrate was concentrated to dryness. The resultingresidue was purified by prep-TLC (10% MeOH/CH₂Cl₂) to give the pureCompound 31 (56.2 mg, yield 65% from Compound 31g), MS [M+1]⁺ 587.1.

Preparative Example 32

In a 25 ml round-bottomed flask, Compound 42b (0.142 g, 0.23 mmol, 1.0equiv) was taken up in 3 mL of dichloroethane under a N₂ atmosphere andthe reaction mixture was treated with Et₃N (0.0.48 ml, 0.34 mmol, 1.5equiv) followed by 3-chlorosulfonyl propyl chloride (0.037 ml, 0.3 mmol,1.2 equiv). The reaction mixture was stirred at room temperatureovernight. The progress of the reaction was monitored by TLC (60:40EtOAc/hexane) and MS, which indicated no desired product was formed.Accordingly, the reaction mixture was then heated to reflux. After onehour of heating the reaction was complete. The reaction mixture was thencooled and diluted with CH₂Cl₂, and quenched with 1 N HCl. The organiclayer was dried over Na₂SO₄ and concentrated to give crude Compound 32a(0.11 g), which was used in the next step without further purification.

In a flame dried 15 ml round-bottomed flask, Compound 32a (0.11 g, 0.23mmol, 1.0 equiv) was taken up in dry DMF. To this reaction mixture,1,8-diazabicyclo[5.4.0]undec-7ene (0.044 g, 0.29 mmol, 1.2 equiv) wasadded and the reaction mixture was stirred at room temperatureovernight. The progress of the reaction was monitored by TLC (30:70EtOAc/hexane) and MS. Upon completion of the reaction, the reactionmixture was diluted with EtOAc and quenched with H₂O. The organic layerwas dried over Na₂SO₄ and concentrated to give crude Compound 32b (0.1g). Purification was carried out using BIOTAGE chromatography (30/70EtOAc/hexane) to give purified Compound 32b (0.072 g).

Electrospray MS [M+1] 710.2.

Compound 32b (0.072 g, 0.1 mmol, 1.0 equiv) was dissolved in dry MeOH(1.5 ml) and was treated with 20% Pd(OH)₂ (60% wt.) under an inertatmosphere. The reaction was hydrogenated at atmospheric pressure andthe progress of the reaction was monitored by TLC (40:60 EtOAc/hexane).The reaction was completed in 45 min, and was filtered through CELITE,washed with EtOAc, and concentrated to give a crude product. The crudeproduct was purified using preparative chromatography (60/40EtOAc/hexane) to give Compound 32 (0.04 g, 70%).

Electrospray MS [M+1]576.2.

HRMS (FAB) calculated for C₂₆H₂₈F₆N₃O₂ (M+1) 576.1756, found 576.1764.

Preparative Example 33

In a 25 ml round-bottomed flask, Compound 42b (0.322 g, 0.53 mmol, 1.0equiv) was taken up in 5 ml of CH₂Cl₂ and the reaction mixture wascooled to 0° C. in an ice bath. Et₃N (0.111 mL, 0.79 mmol, 1.5 equiv)followed by 4-chlorobutyryl chloride (0.072 ml, 0.64 mmol, 1.2 equiv)was then added to the reaction mixture, which was slowly warmed to roomtemperature and stirred for 14 hrs. The progress of the reaction wasmonitored by TLC (60:40 EtOAc/hexane eluent) and MS. Upon completion ofthe reaction, the reaction mixture was diluted with CH₂Cl₂ and quenchedwith saturated NaHCO₃ followed by brine. The organic layer was driedover Na₂SO₄ and concentrated to give crude Compound 33a (0.32 g), whichwas used in the next step without further purification.

In a flame dried 25 ml round-bottomed flask, Compound 33a (0.32 g, 0.45mmol, 1.0 equiv) was taken up in dry THF. To this solution, 60% NaH(0.025 g, 0.68 mmol, 1.5 equiv) was added, and the reaction mixture wasstirred at room temperature for 2 hrs. The progress of the reaction wasmonitored by TLC (60:40 EtOAc/hexane) and MS. Upon completion of thereaction, the reaction mixture was diluted with EtOAc and quenched withsaturated NaHCO₃. The organic layer was dried over Na₂SO₄ andconcentrated to give Compound 33b (0.4 g), in the form of a yellow oil,which was used in the next step without further purification.

Compound 33b (0.4 g, 0.59 mmol, 1.0 equiv) was dissolved in dry MEOH(4.0 mL) and was treated with 20% Pd(OH)₂ (60% wt.) under an inertatmosphere. The reaction was hydrogenated at atmospheric pressure andthe progress of the reaction was monitored by TLC (40:60 EtOAc/hexaneeluent). The reaction was completed in 45 min, was filtered throughCELITE and washed using EtOAc and concentrated to give a crude product.Purification of the crude product was carried out using BIOTAGEchromatography (60/40 EtOAc/hexane) to give Compound 33 (0.18 g, 59%).

HRMS (FAB) calculated for C₂₆H₂₈F₆N₃O₂ (M+1) 540.2086, found 540.2078.

Preparative Example 34

In a 25 ml round-bottomed flask, Compound 42c (0.23 g, 0.38 mmol, 1.0equiv) was taken up in 3 mL of CH₂Cl₂, and the reaction mixture wascooled to 0° C. in an ice bath. Et₃N (0.079 ml, 0.57 mmol, 1.5 equiv)followed by 4-chlorobutyryl chloride (0.051 ml, 0.45 mmol, 1.2 equiv)was then added to the reaction mixture, which was slowly warmed to roomtemperature and was stirred for 14 hrs. The progress of the reaction wasmonitored by TLC (60:40 EtOAc/hexane eluent) and MS. Upon completion ofthe reaction, the reaction mixture was diluted with CH₂Cl₂ and quenchedwith saturated NaHCO₃ followed by brine. The organic layer was driedover Na₂SO₄ and concentrated to give crude Compound 34a (0.23 g), whichwas used in the next step without further purification.

In a flame dried 25 ml round-bottomed flask, Compound 34a (0.23 g, 0.38mmol, 1.0 equiv) was taken up in dry THF (1 mL). To this reactionmixture, 60% NaH (0.022 g, 0.57 mmol, 1.5 equiv) was added and thereaction mixture was stirred at room temperature for 2 hrs. The progressof the reaction was monitored by TLC (60:40 EtOAc/hexane eluent) and MS.Upon completion of the reaction, the reaction mixture was diluted withEtOAc and quenched with saturated NaHCO₃. The organic layer was driedover Na₂SO₄ and concentrated to give Compound 34b (0.21 g) in the formof a yellow oil, which was used in the next step without furtherpurification.

Electrospray MS [M+1] 674.2.

Compound 34b (0.21 g, 0.31 mmol, 1.0 equiv) was dissolved in dry MeOH(2.0 mL) and was treated with 20% Pd(OH)₂ (40% wt.) under an inertatmosphere. The reaction mixture was hydrogenated at atmosphericpressure and the progress of the hydrogenation was monitored by TLC(40:60 EtOAc/hexane eluent). After 45 min, the reaction mixture wasfiltered through CELITE, washed with EtOAc, and concentrated to give acrude product. The crude product was purified using BIOTAGEchromatography (60/40 EtOAc/hexane), to give Compound 34 (0.10 g, 59%).

HRMS (FAB) calculated for C₂₆H₂₈F₆N₃O₂ (M+1) 540.2086, found 540.2078.

Preparative Example 35

Compound 35 was prepared using a procedure similar to procedure forpreparing Compound 23e in Example 23.

Likewise, Compound 35b was prepared by a procedure similar to theprocedure used to prepare Compound 23f in Example 23.

Compound 35c was prepared by a procedure similar to the procedure usedto prepare Compound 23g in Example 23.

Compound 35d was prepared by a procedure similar to the procedure forpreparing Compound 23 in Example 23.

Compound 35e was prepared by a procedure similar to the procedure forpreparing Compound 23h in Example 23.

Compound 35f was preparing by a procedure similar to the procedure forpreparing Compound 42e in Example 42.

Compound 35g was prepared by a procedure similar to the procedure forpreparing Compound 42g in Example 42.

Compound 35 was prepared by a procedure similar to the procedure forpreparing Compound 42 in Example 42. HRMS calculated for C₂₅H₂₃F₆N₅O₂(M+H) 540.1834, found 540.1822.

Preparative Example 36

Compound 36a was prepared by a procedure similar to the procedure forpreparing Compound 47 in Example 47.

Compound 36 was prepared by a procedure similar to the procedure forpreparing Compound 23 in Example 23. HRMS calculated for C₂₄H₂₅F₆N₃O₃S(M+H) 550.1599, found 550.1603.

Preparative Example 37

Compound 37a was prepared by a procedure similar to the procedure forpreparing compound 47 in Example 47.

Compound 37 was prepared using a procedure similar to the procedure forpreparing Compound 23 in Example 23. HRMS calculated for C₂₄H₂₅F₆N₃O₃S(M+H) 550.1599, found 550.1603.

Preparative Example 38

To a solution of Compound 31g (640 mg, 0.93 mmol) in 10 mL CH₂Cl₂maintained at −78° C. was bubbled O₃ gas until the reaction mixture turnblue. The reaction mixture was then purged with nitrogen until it becamecolorless. TBAI (412 mg, 1.11 mmol) was then added and the reactionmixture was stirred at 20° C. for 2 h. The reaction mixture was dilutedwith diethyl ether, washed with saturated aqueous Na₂S2O₃, water andbrine, and the dried and concentrated. The resulting residue wasdissolved in EtOH (22 mL) and NaOAc (262.7 mg, 3.2 mmol) andhydroxylamine hydrochloride salt (222 mg, 3.2 mmol) were added, and themixture was stirred overnight. The reaction mixture was thenconcentrated and the residue was partitioned between 20 mL EtOAc andwater. The organic layer was dried and concentrated. The crudeintermediate was dissolved in toluene (6.8 mL) followed by the additionof 1,1′-oxallyldiimidazole (165 mg, 1.8 mmol) and the mixture was heatedat 80° C. for 2 h. After cooling the reaction mixture to 23° C., thetoluene solution was loaded to a silica gel column and eluted with20-100% EtOAc/hexanes to give product Compound 38a. MS [M+1]⁺ 688.1.

Using a procedure similar to that of Example 31, Step 6, Compound 38awas hydrogenated to give Compound 38. MS [M+1]⁺ 554.1.

Preparative Example 39 and 40

Compounds 39 and 40 were prepared using a procedure similar to theprocedure for preparing Compound 38. HRMS calculated for C₂₃H₂₃F₆N₃O(M+H) 472.1824, found 472.1820.

Preparative Example 41

In a 25 mL round-bottomed flask Compound 42b (0.15 g, 0.248 mmol, 1.0equiv) was dissolved in 6 mL of DCE. Trimethylsilyl isocyanate (0.51 mL,3.72 mmol, 15.0 equiv) was added and the reaction mixture was refluxedat 80° C. overnight. The reaction mixture was cooled and quenched withsaturated NaHCO₃ (10 mL). The aqueous phase was extracted with EtOAc(2×10 mL). The organic layers were washed with brine (5 mL), dried overMgSO₄, and concentrated. The crude product was purified by preparativeTLC (1:1 EtOAc:hexanes) to yield 0.060 g (37%) of Compound 41a.

Compound 41 was prepared by a procedure similar to procedure forpreparing Compound 23 in Example 23. HRMS calculated for C₂₄H₂₄F₆N₄O₂(M+H) 515.1882, found 515.1874.

Preparative Example 42

Compound 41a (6.87 g, 11.86 mmol) in EtOH (7 mL) was added to a solutionof NaCN (0.767 g), NH₄Cl (0.889 g) and NH₃H₂O (3.84 mL) in EtOH (7.0 mL)and water (7.0 mL) at room temperature in a sealed tube. The sealed tubewas then heated at 60° C. for 12 hours before it was cooled down to roomtemperature. The reaction mixture was diluted with EtOAc (200 mL) andwashed with water (50 mL). The aqueous phase was extracted with EtOAc(3×30 mL). The combined organic layers were washed with brine (30 mL),and dried over MgSO₄. After filtration and concentration, the crudeproduct was purified using BIOTAGE chromatography (hexane/EtOAc, v/v=7/2to 5/2) to give Compound 42b (2.6 g, 36%) and Compound 42c (1.8 g, 25%).

Phosgene (6.67 mL, 12.4 mmol, 20% in toluene) was added dropwise to avigorously stirred mixture of Compound 42b (1.5 g, 2.48 mmol) in CH₂Cl₂(30 mL) and a saturated NaHCO₃ solution (30 mL) at 0° C. The mixture wasstirred at 0° C. for 3 hours before it was diluted with CH₂Cl₂ (50 mL)and the aqueous phase was separated from the organic phase. The organicphase was washed with a cold aqueous NH₄Cl solution, brine, and driedover MgSO₄. The solvent was reduced to a volume of about 5 mL underreduced pressure, at room temperature, to remove excess phosgene. Theresidue was dissolved in CH₂Cl₂ (15 mL) and treated with NH₂NHC(O)H(0.446 g, 7.44 mmol) and pyridine (1.2 mL, 14.88 mmol) at roomtemperature. The resulting solution was stirred at room temperature for12 hours. The reaction mixture was then diluted with EtOAc (200 mL) andwashed with HCl (50 mL, 0.5 N). The aqueous phase was extracted withEtOAc (3×30 mL). The combined organic layers were washed with brine (30mL), and dried over MgSO₄. After filtration and concentration, the crudeproduct was purified using BIOTAGE chromatography eluted withhexane/EtOAc (v/v=1/2 to 1/7) to give Compound 42d (1.1 g, 64%).

TMSCI (50 μL) was added to a stirring mixture of Compound 42d (15 mg,0.0217 mmol) and LiI (2.9 mg, 0.0217 mmol) in HMDS (0.5 mL) at roomtemperature. The resulting reaction mixture was heated at 140° C. (bathtemperature) for 30 hours before it was cooled down to room temperature.The reaction mixture was diluted with EtOAc (25 mL) and washed with HCl(5 mL, 1.0 N). The aqueous phase was extracted with EtOAc (3×10 mL). Thecombined organic layers were washed with brine (10 mL), and dried overMgSO₄. After filtration and concentration, the crude product waspurified using preparative TLC (hexane/EtOAc, v/v=6/4) to give Compound42 (4 mg, 34%).

Alternate Procedure for Example 42

Alternatively, Compound 42 can also be prepared from Compound 23g asfollows

In a 10 mL round-bottomed flask, Compound 23g (0.02 g, 0.037 mmol, 1.0equiv) was dissolved in DCM (3 mL) and the reaction mixture was cooledto 0° C. Dess-Martin periodinane (0.02 g, 0.048 mmol, 1.3 equiv) wasadded and the reaction mixture was stirred under nitrogen at roomtemperature for 45 minutes. The progress of the reaction was monitoredby TLC (9/1 EtOAC/MeOH eluent), and the reaction was quenched after 1.5hrs, by pouring the reaction mixture into separatory funnel containingsaturated Na₂S₂O₃/NaHCO₃ solution (1:1) (5 mL). The mixture in theseparatory funnel was shaken vigorously, and the aqueous layer wasextracted with Et₂O (2×5) and dried over MgSO₄ and concentrated to givecrude Compound 42e (0.02 g), which was used in the next step withoutfurther purification.

Step B:

In a 25 mL round-bottomed flask, Compound 42f (0.09 g, 0.13 mmol, 1.0equiv) and sodium acetate (0.032 g, 0.39 mmol, 3.0 equiv) were dissolvedin EtOH (6 mL), to which hydroxylamine hydrochloride (0.056 g, 0.080mmol, 6.0 equiv) was added. The reaction mixture was stirred undernitrogen at room temperature overnight. The reaction mixture was thendiluted with EtOAc (15 mL), quenched with saturated NaHCO₃ (5 mL), andthe organic layer was washed using brine (5 mL) and dried over MgSO₄ togive crude Compound 42g (0.95 g), which was used in the next stepwithout further purification.

In a 50 mL round-bottomed flask, Compound 42g (1.1 g, 0.59 mmol, 1.0equiv) was dissolved in benzene (25 mL). 1,1′-oxalyldiimidazole (0.302g, 1.89 mmol, 1.5 equiv) was added to the solution, and the reactionmixture was heated to 75° C. under nitrogen for 4 hrs. The reactionmixture was then quenched with water (20 mL), diluted with EtOAc (30mL), dried over MgSO₄ and concentrated to give a crude product. Thecrude product was purified using BIOTAGE chromatography (1/1EtOAc/hexanes) to give Compound 42h (0.7 g, 66% over three steps).

In a 50 mL round-bottomed flask, Compound 42i (0.5 g, 0.742 mmol, 1.0equiv) was taken up in acetonitrile (9 mL). The reaction mixture wascooled to 0° C., and TMSI (0.742 mL, 5.19 mmol, 7.0 equiv) was addeddropwise via syringe. The reaction mixture was stirred overnight at roomtemperature. The progress of the reaction was monitored by MS, whichindicated some starting material was still present. The reaction mixturewas quenched using saturated Na₂S₂O₃/NaHCO₃ (1:1) (10 mL) and dilutedwith EtOAc (20 mL). The organic layer was washed with brine (10 mL),dried over MgSO₄, and concentrated to yield a crude product. The crudeproduct was purified using BIOTAGE chromatography (60/40 EtOAc/hexanes)to give Compound 42 (0.4 g). HRMS calculated for C₂₅H₂₃F₆N₅O₂ (M+H)540.1834, found 540.1813.

Preparative Example 43

Compound 43a was prepared by a procedure similar to the procedure forpreparing Compound 28a.

Compound 43b was prepared by a procedure similar to the procedure forpreparing Compound 45c.

Compound 43 was prepared by a procedure similar to the procedure forpreparing Compound 28 (step c).

Preparative Example 44

In a 50 mL round-bottomed flask, Compound 44a (1.1 g, 2.31 mmol, 1.0equiv) was dissolved in acetic acid (20 mL), and the resulting reactionmixture was cooled to 0° C. Zn powder (1.51 g, 23.1 mmol, 10.0 equiv)was added and the mixture was refluxed for 2.5 hr. The reaction mixturewas then filtered through CELITE, concentrated, diluted with EtOAc (30mL), and neutralized with saturated NaHCO₃ (30 mL). The aqueous phasewas extracted with EtOAc (2×10 mL), washed with brine (20 mL), driedover MgSO₄ and concentrated. The crude product was purified using afilter column to yield 1.0 g (99%) of Compound 44b.

Compound 44c was prepared by a procedure similar to the procedure forpreparing Compound 45b.

Compound 44d was prepared by a procedure similar to the procedure forpreparing Compound 45c.

Compound 44e was prepared by a procedure similar to the procedure forpreparing Compound 45d.

In a 10 mL round-bottomed flask, Compound 44e (0.34 g, 0.54 mmol, 1.0equiv) was taken up in 5.5 mL of MeOH/H₂O (10:1). The round-bottomedflask was degassed, and Pd/C (10 wt %, 0.18 g) was added followed byHCO₂NH₄ (0.174 g, 2.68 mmol, 5.0 equiv). The resulting heterogeneousmixture was refluxed overnight, cooled, filtered through CELITE,concentrated, diluted with EtOAc (10 mL), washed with saturated NaHCO₃(10 mL), and dried over Na₂SO₄. The crude product was purified byBIOTAGE chromatography (9:1 EtOAc:MeOH) to yield 0.11 g (38%) ofCompound 44. HRMS calculated for C₂₅H₂₆F₆N₄O₃ (M+H) 545.1987, found545.1988.

Preparative Example 45 and 46

Compound 41a (2.8 g, 4.59 mmol, 1.0 equiv) was taken up in ethanol (15mL). Raney nickel was added to the solution, and the reaction mixturewas hydrogenated in a Parr shaker at 60 psi. The progress of thehydrogenation was monitored by TLC (4/1 EtOAc/hexanes). After 3 hours,the reaction mixture was then filtered through CELITE, washed withethanol (30 mL) and concentrated. The crude product was purified byBIOTAGE chromatography (4/1 EtOAc/hexanes), to give Compound 45a (1.75g, 65%).

In a 50 mL round-bottomed flask, Compound 45a (1.0 g, 1.72 mmol, 1.0equiv) was dissolved in dry THF (20 mL) and cooled to 0° C. A solutionof tert-butyl carbazate (0.228 g, 1.72 mmol, 1.0 equiv) and carbonyldiimidazole (0.335 g, 2.06 mmol, 1.2 equiv), which was previouslystirred in dry THF (10 mL), was added to the above cooled solution viacannula. The reaction mixture was allowed to warm to room temperatureand was stirred overnight. The reaction mixture was then concentratedand purified by BIOTAGE chromatography (1/1 EtOAc/hexanes) to giveCompound 45b (0.85 g, 67%).

In a 50 mL round-bottomed flask, Compound 45b (0.39 g, 0.53 mmol, 1.0equiv) was dissolved in CH₂Cl₂ (10.0 mL) and cooled to 0° C.Trifluoroacetic acid (1.02 mL, 13.2 mmol, 25.0 equiv) was added to thesolution, and the reaction mixture was allowed to stir at roomtemperature. The progress of the reaction was monitored by MS (i.e.,disappearance of starting material). The reaction mixture wasconcentrated after 7 h, and was used in the next step without anyfurther purification. The crude intermediate was dissolved in THF (5 mL)and cooled to 0° C. A 20% aqueous solution of NaOH (5.0 mL) was added,followed by methoxyacetyl chloride (0.096 mL, 1.06 mmol, 2.0 equiv). Thereaction mixture was allowed to stir at room temperature overnight, andwas then diluted with H₂O (10 mL), extracted with Et₂O (2×10 mL), washedwith brine (10 mL), dried over MgSO₄ and concentrated to yield crudeCompound 45c (0.35 g, 95%), which was used in the next step without anyfurther purification.

In a 25 mL round-bottomed flask, Compound 45c (0.35 g, 0.49 mmol, 1.0equiv) was dissolved in EtOH (3.0 mL). 3.0 mL of a 6 M solution of NaOHwas added and the reaction mixture was refluxed overnight. The reactionmixture was then concentrated and purified by preparative TLC (EtOAc) togive 0.145 g (42%) of Compound 45d.

In a 10 mL round-bottomed flask, Compound 45d (0.125 g, 0.18 mmol, 1.0equiv) was dissolved in 3 mL MeOH. Pd(OH)₂ (0.010 g, 0.072 mmol, 40 wt%) was added, and the heterogeneous mixture was hydrogenated at roomtemperature. The progress of the hydrogenation was monitored by MS. Thereaction mixture was filtered through CELITE, concentrated and purifiedby preparative TLC (EtOAc) affording a mixture of Compounds 45 and 46(0.008 g, 8%). HRMS calculated for C₂₆H₂₈F₆N₄O₃ (M+H) 559.2144, found559.2146.

Preparative Example 47 and 48

In a 10 mL round-bottomed flask, a mixture of Compounds 49 and 50 (0.025g, 0.047 mmol, 1.0 equiv) was dissolved in 2 mL of DCM and cooled to 0°C. Triethylamine (0.0073 mL, 0.052 mmol, 1.1 equiv) was added, followedby MeSO₂Cl (0.004 mL, 0.052 mmol, 1.1 equiv). The reaction mixture wasallowed to stir overnight. The reaction mixture was then diluted withEtOAc (10 mL) and quenched with saturated NaHCO₃ (5 mL). The aqueousphase was extracted with EtOAc (2×5 mL), dried over Na₂SO₄, andconcentrated. The crude product was purified by preparative TLC (4:1EtOAc/hexanes) to give 0.028 g (100%) of a mixture of Compounds 47 and48. HRMS calculated for C₂₅H₂₇F₆N₅O₄S (M+H) 608.1766, found 608.1785.

Preparative Example 49 and 50

Compound 49a (0.50 g, 0.77 mmol, 1.0 equiv) was added to a 50 mLround-bottomed flask. Fuming HNO₃ (3 mL) was then added to the flask,and the resulting reaction mixture was allowed to stand for 1 h. Afterthe reaction was complete, ice (10 g) was added. The reaction mixturewas diluted with EtOAc (25 mL) and neutralized with saturated NaOH (3mL). The aqueous phase was extracted with EtOAc (2×10 mL). The organiclayers were washed with brine (10 mL), dried over MgSO₄, andconcentrated. The crude product was purified by BIOTAGE Chromatography(7:3 EtOAc:hexanes) to give 0.45 g (79%) of Compound 49b.

Compounds 49 and 50 were prepared by a procedure similar to theprocedure for preparing Compound 44b. HRMS calculated for C₂₄H₂₅F₆N₅O₂(M+H) 530.1991, found 530.1977.

Preparative Example 51

Compound 55 (0.078 g, 0.11 mmol, 1.0 equiv) was dissolved in 7 M ammoniain MeOH (3.0 mL) and was added to a small Parr bomb, which was heated to80° C. for 2 days. The progress of the reaction was monitored by TLC(9/1 CH₂Cl₂/MeOH). Upon completion of the reaction, the reaction mixturewas concentrated to give a crude product in the form of a white solid.The crude product was purified using BIOTAGE chromatography (2:1 to 4:1EtOAc/Hexane) to give Compound 51a as a white solid (0.48 g).

Electrospray MS [M+1] 692.2.

Compound 51a (0.045 g, 0.065 mmol, 1.0 equiv.) was dissolved in dry MeOH(2.0 mL) and was treated with 10% Pd/C (40% wt.) followed by ammoniumformate (0.02 g, 0.03 mmol, 5.0 equiv.) under an inert atmosphere. Thereaction mixture was heated to reflux and the progress of the reactionwas monitored by TLC (100% EtOAc). The reaction was completed in 1 hr.The reaction mixture was filtered through CELITE, washed with EtOAc andconcentrated under vacuum. The resulting residue was taken up in EtOAc,washed with saturated NaHCO₃, followed by brine and H₂O to give thedesired product, Compound 51 in the form of a white solid, which wasconverted to its HCl salt (0.034 g, 94%).

HRMS (FAB) calculated for C₂₆H₂₈F₆N₃O₂ (M+1) 558.19242, found 558.19398.

Preparative Example 52

Compound 53 (18.1 mg, 0.0325 mmol) in EtOH (2.5 mL) was treated withMeONH₂.HCl (24.4 mg, 0.292 mmol) and NaOAc (12.0 mg, 0.146 mmol) at roomtemperature. The reaction mixture was stirred at 60° C. for 12 hr, thendiluted with EtOAc (20 mL) and washed with aqueous NaHCO₃. The aqueousphase was extracted with EtOAc (3×10 mL). The combined organic layerswere washed with water (10 mL), brine (10 mL), and dried over MgSO₄.After filtration and concentration, the crude product was purified usingpreparative TLC (hexane/EtOAc, v/v=1/1 to 1/9) to give Compound 52 (16mg, 84%). Electrospray MS [M+1] 586.1.

Preparative Example 53

Dess-Martin periodinane (0.234 g, 0.553 mmol) was added to a mixture ofCompound 23h (0.25 g, 0.369 mmol) and NaHCO₃ (0.232 g, 2.76 mmol) inCH₂Cl₂ (5.0 mL) at room temperature. The reaction mixture was stirredfor 1 hour before it was diluted with EtOAc (50 mL) and water (10 mL).The organic phase was washed with saturated Na₂S₂O₃ solution (3×15 mL).The combined aqueous phases were extracted with EtOAc (3×15 mL). Thecombined organic layers were washed with NaOH solution (15 mL, 1.0 N),water (10 mL), brine (15 mL), and dried over MgSO₄. After filtration andconcentration, the crude aldehyde (0.25 g) was taken up in anhydrous THF(4.0 mL) and was treated with MeMgBr (0.49 mL, 1.48 mmol, 3.0 M in Et₂O)at −78° C. The reaction temperature was slowly increased to roomtemperature and the reaction was quenched in 2 hours with the slowaddition of saturated aqueous NH₄Cl solution (10 mL). The reactionmixture was then diluted with EtOAc (50 mL) and neutralized with 0.5 NHCl until the aqueous phase was slightly acidic. The aqueous phase wasextracted with EtOAc (3×15 mL). The combined organic layers were washedwith water (10 mL), brine (10 mL), and dried over MgSO₄. Afterfiltration and concentration, the crude secondary alcohol (0.26 g) wastaken up in CH₂Cl₂ (5.0 mL) and treated with Dess-Martin periodinane(0.468 g, 1.11 mmol) and NaHCO₃ (0.466 g, 5.55 mmol) at roomtemperature. The reaction mixture was stirred for 1 hour before it wasdiluted with EtOAc (50 mL) and water (10 mL). The organic phase waswashed with saturated Na₂S₂O₃ solution (3×15 mL). The combined aqueousphases were extracted with EtOAc (3×15 mL). The combined organic layerswere washed with NaOH solution (15 mL, 1.0 N), water (10 mL), brine (15mL), and dried over MgSO₄. After filtration and concentration, the crudeproduce was purified using BIOTAGE chromatography (hexane/EtOAc,v/v=1/1) to give Compound 53a (0.11 g, 43% for 3 steps).

Compound 53a (107 mg, 0.155 mmol) in EtOH (5.0 mL) was treated at roomtemperature with Pd(OH)₂/C (21.5 mg, 10 wt %) and was hydrogenated witha H₂ balloon for 30 minutes. The reaction solution was filtered througha short pad of CELITE and the residue was washed with EtOH (15 mL). Thesolvent was removed under reduced pressure and the crude product waspurified using BIOTAGE chromatography (hexane/EtOAc, v/v=1/3 to 1/9) togive Compound 53 (66 mg, 76%). Electrospray MS [M+1]⁺ 557.3.

Preparative Example 54

Compound 53 (14.3 mg, 0.0257 mmol) in EtOH (2.5 mL) was treated withHONH₂.HCl (10.7 mg, 0.154 mmol) and NaOAc (6.3 mg, 0.077 mmol) at roomtemperature. The reaction mixture was stirred at 60° C. for 12 hr, thendiluted with EtOAc (20 mL) and washed with aqueous NaHCO₃. The aqueousphase was extracted with EtOAc (3×10 mL). The combined organic layerswere washed with water (10 mL), brine (10 mL), and dried over MgSO₄.After filtration and concentration, the crude product was purified usingpreparative TLC (hexane/EtOAc, v/v=1/2) to give Compound 54 (11 mg,75%). Electrospray MS [M+1]⁺ 572.1.

Preparative Example 55

Dess-Martin Periodinane (0.12 g, 0.284 mmol) was added to a mixture ofCompound 23h (96.3 mg, 0.142 mmol) and NaHCO₃ (0.12 g, 1.42 mmol) inCH₂Cl₂ (3.0 mL) at room temperature. The reaction mixture was stirredfor 1 hour before it was diluted with addition of EtOAc (50 mL) andwater (10 mL). The organic phase was washed with saturated Na₂S₂O₃solution (3×15 mL). The combined aqueous phases were extracted withEtOAc (3×15 mL). The combined organic layers were washed with NaOHsolution (15 mL, 1.0 N), water (10 mL), brine (15 mL), and dried overMgSO₄. After filtration and concentration, the crude aldehyde (96.3 mg)was taken up in tert-butanol (2.0 mL) and water (0.5 mL) and treatedwith NaH₂PO₄H₂O (39.2 mg, 0.284 mmol), NaClO₂ (44.9 mg, 0.497 mmol) and2-methyl-2-butene (0.105 mL, 0.994 mmol) successively. The reactionmixture was stirred for 2 hours and then diluted with EtOAc (20 mL) andwashed with aqueous NH₄Cl. The aqueous phase was extracted with EtOAc(3×10 mL). The combined organic layers were washed with water (10 mL),brine (10 mL), and dried over MgSO₄. After filtration and concentration,the crude acid (95 mg) was dissolved in benzene (2.8 mL) and MeOH (0.7mL). The resulting solution was treated with TMSCHN₂ (82.2 μL, 0.164mmol) at room temperature and stirred for 20 minutes. The solvent wasremoved under reduced pressure and the crude product was purified usingBIOTAGE chromatography (hexane/EtOAc, v/v=2/3) to give Compound 55a (70mg, 35% for 3 steps).

Compound 55a (38 mg, 0.0537 mmol) in EtOH (3.0 mL) was treated at roomtemperature with Pd(OH)₂/C (7.6 mg, 10 wt %) and was hydrogenated with aH₂ balloon for 30 minutes. The reaction solution was filtered through ashort pad of CELITE and the residue was washed with EtOH (15 mL). Thesolvent was removed under reduced pressure and the crude product waspurified using preparative TLC (hexane/EtOAc, v/v=2/3) to give Compound55 (24 mg, 78%). Electrospray MS [M+1]⁺ 573.1.

Preparative Example 56

Compound 56a (15 mg, 0.0227 mmol) in EtOH (2.0 mL) was treated at roomtemperature with Pd(OH)₂/C (3.6 mg, 10 wt %) and was hydrogenated with aH₂ balloon for 30 minutes. The reaction solution was filtered through ashort pad of CELITE and the residue was washed with EtOH (15 mL). Thesolvent was removed under reduced pressure and the crude product wastaken up in Et₂O (0.5 mL) and treated with HCl in ether (0.23 mL, 0.23mmol, 1.0 M in ether). The mixture was stirred at room temperature for12 hours. The mixture was then diluted with EtOAc (20 mL) and washedwith aqueous NaOH (5 mL, 0.5 N). The aqueous phase was extracted withEtOAc (3×10 mL). The combined organic layers were washed with water (10mL), brine (10 mL), and dried over MgSO₄. After filtration andconcentration, the crude product was purified using preparative TLC(hexane/EtOAc, v/v=1/1) to give Compound 56 (8.5 mg, 67%). ElectrosprayMS [M+1]⁺ 563.1.

Preparative Example 57

MsCl (11.7 μL, 0.151 mmol) was added to a solution of Compound 23h (42.8mg, 0.063 mmol) and Et₃N (26.4 μL, 0.189 mmol) in CH₂Cl₂ (1.0 mL) atroom temperature. The reaction mixture was quenched with water (5.0 mL)after 30 minutes and diluted with CH₂Cl₂ (15 mL). The aqueous phase wasextracted with CH₂Cl₂ (3×10 mL). The combined organic layers were washedwith water (10 mL), brine (10 mL), and dried over MgSO₄. Afterfiltration and concentration, the crude mesylate (44 mg, 0.0582 mmol)was taken up in anhydrous DMF (2.0 mL) and treated with NaBH₄ (11.0 mg,0.291 mmol). The reaction mixture was heated at 90° C. for 1 hour beforeit was cooled down to room temperature. The reaction mixture was thendiluted with EtOAc (20 mL) and washed with aqueous HCl (5 mL, 1.0 M).The aqueous phase was extracted with EtOAc (3×10 mL). The combinedorganic layers were washed with water (3×10 mL), brine (10 mL), anddried over MgSO₄. After filtration and concentration, the crude productwas purified using preparative TLC (hexane/EtOAc, v/v=3/2) to giveCompound 57a (18 mg, 43%) and Compound 56a (15 mg, 36%).

Compound 57a (18 mg, 0.027 mmol) in EtOH (3.0 mL) was treated at roomtemperature with Pd(OH)₂/C (3.6 mg, 10 wt %) and was hydrogenated with aH₂ balloon for 30 minutes. The reaction solution was filtered through ashort pad of CELITE and the residue was washed with EtOH (15 mL). Thesolvent was removed under reduced pressure and the crude product waspurified using preparative TLC (hexane/EtOAc, v/v=1/1) to give Compound57 (10 mg, 70%). Electrospray MS [M+1]⁺ 529.1.

Preparative Example 58

Compound 19 (10.0 mg, 0.0175 mmol) in EtOH (1.5 mL) was treated withMeONH₂.HCl (14.6 mg, 0.175 mmol) and NaOAc (7.2 mg, 0.0876 mmol) at roomtemperature. The reaction mixture was stirred at 60° C. for 12 hr, andwas then diluted with EtOAc (20 mL) and washed with aqueous NaHCO₃. Theaqueous phase was extracted with EtOAc (3×10 mL). The combined organiclayers were washed with water (10 mL), brine (10 mL), and dried overMgSO₄. After filtration and concentration, the crude product waspurified using preparative TLC (hexane/EtOAc, v/v=2/3) to give Compound58 (10.5 mg, 100%). Electrospray MS [M+1]⁺ 600.1.

Preparative Example 59

To a solution of Compound 59a (0.53 g, 0.76 mmol) in CH₂Cl₂ (4 mL) wasadded Et₃N (0.14 mL, 0.98 mmol). The reaction mixture was cooled to −78°C. and acetyl chloride (0.065 mL, 0.91 mmol) was added. The reactionmixture was slowly warmed to room temperature and stirred for 72 hours.Additional Et₃N (0.068 mL) and acetyl chloride (0.033 mL) was added tothe reaction mixture, which was then stirred at room temperature for 4hours. The reaction mixture was concentrated and purified with BIOTAGEchromatography (hexane/EtOAc, v/v=3/2) to give Compound 59b (0.5 g).

BCl₃ (3.7 mL, 3.7 mmol, 1.0 M in hexane) was added dropwise to astirring solution of Compound 59b (0.55 g, 0.74 mmol) in CH₂Cl₂ (9 mL)at −78° C. The reaction was quenched in 1 hour by the addition ofaqueous NaHCO₃ solution (50 mL) at −78° C. The reaction mixture wasdiluted with EtOAc (200 mL) and washed with saturated aqueous NaHCO₃(100 mL), and dried over Na₂SO₄. The mixture was filtered andconcentrated to give crude Compound 59c (0.4 g), which was used in thenext reaction without further purification.

Dess-Martin periodinane (0.12 g, 0.28 mmol) was added to a mixture ofCompound 59c (0.12 g, 0.18 mmol) and NaHCO₃ (0.17 g, 2.0 mmol) in CH₂Cl₂(5.0 mL) at room temperature and stirred for 45 minutes. AdditionalDess-Martin periodinane (50 mg) was added to the reaction mixture andstirred at room temperature for 2 hours. The reaction mixture was thenconcentrated and purified with BIOTAGE chromatography (hexane/EtOAc,v/v=1/1) to give Compound 59d (0.1 g).

A mixture of Compound 59d (0.11 g, 0.17 mmol), potassium bicarbonate (26mg, 0.19 mmol), tosylmethyl isocyanide (36 mg, 0.19 mmol) and methanol(3 mL) was heated at 80° C. for 48 hours. The reaction mixture was thenconcentrated and diluted with EtOAc (200 mL) and washed with saturatedaqueous NaHCO₃ (2×100 mL). The organic layer was dried over Na₂SO₄,filtered and concentrated. The crude product was purified with BIOTAGEchromatography (hexane/EtOAc, v/v=2/3 to 0/100) to give Compound 59e (50mg).

Compound 59d (0.31 mg, 0.45 mmol) in MeOH (10.0 mL) was treated at roomtemperature with Pd(OH)₂/C (0.2 g, 20 wt %) and was hydrogenated with aH₂ balloon for 2 hours. The reaction solution was filtered through ashort pad of CELITE and the residue was washed with MeOH (30 mL). Thesolvent was removed under reduced pressure and the crude product waspurified with BIOTAGE chromatography (EtOAc/MeOH, v/v=9/1) to givemixture of two isomers (190 mg), which were further purified by HPLC(chiral OD column) with hexane/IPA (v/v=9/1) to give Compound 59 (90mg).

Preparative Example 60

To a solution of Compound 60a (0.26 g, 0.43 mmol) in CH₂Cl₂ (4 mL) at 0°C. was added Et₃N (0.071 mL, 0.51 mmol) followed by ethylchloroformate(0.052 mL, 0.56 mmol), and the reaction mixture was stirred for 1 hour.To the reaction mixture was then added sodium azide (64 mg, 0.98 mmol)and tetrabutylammonium hydrogen sulfate (43 mg, 0.13 mmol) and stirringwas continued for 1 hour. The reaction mixture was then diluted withCH₂Cl₂ (100 ml) and washed with water (1×100 mL) and brine (1×100 mL).The organic layer was dried over Na₂SO₄, filtered and concentrated. Theresidue was dissolved in dry toluene (4 ml) and heated to 80° C. for 2hours and then cooled to room temperature. TMSN₃ (0.13 mL, 0.94 mmol)was added and the reaction mixture was heated to −110° C. for 18 hours.The reaction mixture was then cooled to room temperature, concentratedand purified by BIOTAGE chromatography (hexane/EtOAc, v/v=2/1, followedby MeOH/EtOAc, v/v=1/99) to give Compound 60b (0.17 g).

Compound 60b (0.17 mg, 0.26 mmol) in MeOH (10.0 mL) was treated at roomtemperature with Pd(OH)₂/C (15 mg, 20 wt %) and was hydrogenated with aH₂ balloon for 2 hours. The reaction solution was filtered through ashort pad of CELITE and the residue was washed with MeOH (30 mL). Thesolvent was removed under reduced pressure and the crude product waspurified by BIOTAGE chromatography (EtOAc/MeOH, v/v=98/2) to giveCompound 60 (20 mg).

While the present invention has been described in conjunction with thespecific embodiments set forth above, many alternatives, modificationsand variations thereof will be apparent to those of ordinary skill inthe art. All such alternatives, medications and variations are intendedto fall within the spirit and scope of the present invention.

1. A compound of formula I:

or pharmaceutically acceptable salts thereof, wherein; R¹ and R² areselected from the group consisting of alkyl, haloalkyl, alkylsubstituted with one or more hydroxyl groups, —CN, alkynyl, —N(R⁶)₂,—N(R⁶)—S(O₂)-alkyl, N(R⁶)C(O)—N(R⁹)₂, -alkylene-CN, -cycloalkylene-CN,-alkylene-O-alkyl, —C(O)-alkyl, —C(═N—OR⁵)-alkyl, [—(C(O)—N(R⁹)₂],—C(O)—O-alkyl, -alkylene-C(O)-alkyl, -alkylene-C(O)—O-alkyl,-alkylene-C(O)—N(R⁹)₂,

with the proviso that at least one of R¹ and R² is —CN,

W is ═C(R⁸)— or ═N—; X is —C(O)— or —S(O₂)—; Y is selected from thegroup consisting of —CH₂—, —O—, and —N(R⁶)—C(O)—, with the proviso that:(a) The nitrogen atom of —N(R⁶)—C(O)— is bonded to X, and (b) If R¹and/or R² is

and Y is —O—, X is not —S(O₂)—; Z is —C(R⁷)₂, —N(R⁶)—, or —O—; R³ isselected from the group consisting of H, and unsubstituted alkyl; R⁴ isH; R⁵ is H or alkyl; R⁸ is selected from the group consisting of H,alkyl, cycloalkyl, and aryl; each R⁷ is independently H or alkyl; oreach R⁷, together with the ring carbon to which they are shown attached,form a cycloalkylene ring; R⁸ is selected from the group consisting ofH, alkyl, alkyl substituted with one or more hydroxyl groups, —N(R⁶)₂,—N(R⁶)—S(O₂)-alkyl, —N(R⁶)—S(O₂)-aryl, —N(R⁶)—C(O)-alkyl,—N(R⁶)—C(O)-aryl, alkylene-O-alkyl, and —CN; R⁹ is selected from thegroup consisting of H, alkyl, and aryl, or each R⁹, together with thenitrogen to which they are shown attached, form a heterocycloalkyl ring;Ar¹ is unsubstituted phenyl; Ar² is phenyl substituted with 0-3substituents selected from the group consisting of haloalkyl; n is 0, 1,or 2; and m is 1, 2 or
 3. 2. The compound according to claim 1, whereinthe compound of formula I has the following structure:

and pharmaceutically acceptable salts thereof.
 3. The compound accordingto claim 1, wherein: R³ is unsubstituted alkyl; Ar² is substitutedphenyl; and n is 1, and pharmaceutically acceptable salts thereof. 4.The compound according to claim 2, wherein: R³ is unsubstituted alkyl;Ar² is substituted phenyl; and n is 1, and pharmaceutically acceptablesalts thereof.
 5. The compound according to claim 4, wherein: Ar² is3,5-bis(trifluoromethyl)phenyl, and pharmaceutically acceptable saltsthereof.
 6. The compound according to claim 5, wherein: R³ is —CH₃, andpharmaceutically acceptable salts thereof.
 7. The compound according toclaim 6, wherein: one of R¹ or R² is

and pharmaceutically acceptable salts thereof.
 8. The compound accordingto claim 6, wherein: one of R¹ or R² is

wherein W is ═C(R⁸)— and pharmaceutically acceptable salts thereof. 9.The compound according to claim 6, wherein: one of R¹ and R² is

and pharmaceutically acceptable salts thereof.
 10. The compoundaccording to claim 6, wherein: one of R¹ or R² is —CN, andpharmaceutically acceptable salts thereof.
 11. The compound according toclaim 7, wherein: X is —S(O₂)—; Y is —CH₂—; and m is 2, andpharmaceutically acceptable salts thereof.
 12. The compound according toclaim 7, wherein: X is C(O)—; Y is —CH₂—; and m is 2, andpharmaceutically acceptable salts thereof.
 13. The compound according toclaim 7, wherein: X is —C(O)—; Y is —CH₂—; and m is 3, andpharmaceutically acceptable salts thereof.
 14. The compound according toclaim 7, wherein: X is —C(O)—; Y is —O—; and m is 2, andpharmaceutically acceptable salts thereof.
 15. The compound according toclaim 7, wherein: X is —C(O)—; Y is —CH₂—; and m is 1, andpharmaceutically acceptable salts thereof.
 16. The compound according toclaim 7, wherein: X is —C(O)—; Y is —NH—C(O)—; m is 1, andpharmaceutically acceptable salts thereof.
 17. The compound according toclaim 8, wherein: Z is —NH—; and R⁸ is H, and pharmaceuticallyacceptable salts thereof.
 18. The compound according to claim 8,wherein: Z is —NH—; and R⁸ is —NH—S(O₂)—CH₃, and pharmaceuticallyacceptable salts thereof.
 19. The compound according to claim 8,wherein: Z is —NH—; R⁸ is —CH₂—OH, and pharmaceutically acceptable saltsthereof.
 20. The compound according to claim 8, wherein: Z is —NH—; R⁸is —CH₂—O—CH₃, and pharmaceutically acceptable salts thereof.
 21. Thecompound according to claim 8, wherein: Z is —NH—; R⁸ is —NH₂, andpharmaceutically acceptable salts thereof.
 22. The compound according toclaim 8, wherein: Z is

and R⁸ is H, and pharmaceutically acceptable salts thereof.
 23. Thecompound according to claim 8, wherein: Z is —C(CH₃)₂—; and R⁸ is H, andpharmaceutically acceptable salts thereof.
 24. The compound according toclaim 1, having the Formula IB

wherein R¹ and R³ are selected from the group consisting of: Compound R¹R² 1

—CN 2

—CN 5

—CH₂CN 6 —CH₃

7 —CN

8 —C(O)—O—CH₃

9

—CN 12 —CH₂OH

13

—CH₂OCH₃ 14 —CH₂OCH₃

32

—CN 33

—CN 34 —CN

35 —CN

36 —NH—S(O₂)—CH₃ —CN 37 —CN —NH—S(O₂)—CH₃ 38

—CH₂CN 39 —CN —NH₂ 40 —NH₂ —CN 41 —NH—C(O)—NH₂ —CN 42

—CN.


25. A compound represented by the following formula:

and pharmaceutically acceptable salts thereof.
 26. A compoundrepresented by the following formula:

and pharmaceutically acceptable salts thereof.
 27. A compoundrepresented by the following formula:

and pharmaceutically acceptable salts thereof.
 28. A pharmaceuticalcomposition comprising: at least one compound of claim 1 or apharmaceutically acceptable salt thereof, and at least onepharmaceutically acceptable carrier.
 29. A pharmaceutical compositioncomprising a pharmaceutically acceptable carrier, at least one serotoninreuptake inhibitor, and at least one compound of claim
 1. 30. A purifiedcompound according to claim 1 or a purified pharmaceutically acceptablesalt thereof.